



# Cardiovascular disease and COPD: dangerous liaisons?

Klaus F. Rabe<sup>1,2</sup>, John R. Hurst<sup>3</sup> and Samy Suissa<sup>4,5</sup>

**Affiliations:** <sup>1</sup>Dept of Medicine, University of Kiel, Kiel, Germany. <sup>2</sup>Lung Clinic Großhansdorf, Airway Research Center North (ARCN), Großhansdorf, Germany. <sup>3</sup>Centre for Inflammation and Tissue Repair, Division of Medicine, University College London, London, UK. <sup>4</sup>Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada. <sup>5</sup>Dept of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada.

**Correspondence:** Klaus F. Rabe, LungenClinic Großhansdorf, Airway Research Center North, Woehrendamm 80, Großhansdorf 22927, Germany. E-mail: k.f.rabe@lungenclinic.de

 @ERSpublications  
**CVD and COPD are often comorbid. Their pathophysiology and treatment may affect each other and health outcomes.** <http://ow.ly/v18p30lxmms>

**Cite this article as:** Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? *Eur Respir Rev* 2018; 27: 180057 [<https://doi.org/10.1183/16000617.0057-2018>].

**ABSTRACT** Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently occur together and their coexistence is associated with worse outcomes than either condition alone. Pathophysiological links between COPD and CVD include lung hyperinflation, systemic inflammation and COPD exacerbations. COPD treatments may produce beneficial cardiovascular (CV) effects, such as long-acting bronchodilators, which are associated with improvements in arterial stiffness, pulmonary vasoconstriction, and cardiac function. However, data are limited regarding whether these translate into benefits in CV outcomes. Some studies have suggested that treatment with long-acting  $\beta_2$ -agonists and long-acting muscarinic antagonists leads to an increase in the risk of CV events, particularly at treatment initiation, although the safety profile of these agents with prolonged use appears reassuring. Some CV medications may have a beneficial impact on COPD outcomes, but there have been concerns about  $\beta$ -blocker use leading to bronchospasm in COPD, which may result in patients not receiving guideline-recommended treatment. However, there are few data suggesting harm with these agents and patients should not be denied  $\beta$ -blockers if required. Clearer recommendations are necessary regarding the identification and management of comorbid CVD in patients with COPD in order to facilitate early intervention and appropriate treatment.

## Introduction

Chronic obstructive pulmonary disease (COPD) is a complex respiratory disorder characterised by chronic airflow limitation and an increased inflammatory response of the lung [1]. COPD is associated with many comorbidities [2, 3] (figure 1) and can be one of multiple chronic or acute diseases and medical conditions present within one person [4]. In particular, cardiovascular disease (CVD) and COPD share similar risk factors such as ageing, history of cigarette smoking (or other exposures) and a sedentary lifestyle, and frequently coexist [2, 3, 5].

Historically, many terms and definitions have been inconsistently used to describe the co-existence of diseases [6]. Recently, it was proposed that the term “index disease” should be used to describe the main condition of interest and “comorbidity” for any other medical conditions present at diagnosis of the index disease or later [6]. By contrast, “multimorbidity” is defined simply as the co-existence of two or more chronic diseases [6, 7].

---

This article has been amended according to the erratum published in the December 2018 issue of the European Respiratory Review.

Provenance: Submitted article, peer reviewed.

Received: June 19 2018 | Accepted after revision: Aug 20 2018

Copyright ©ERS 2018. ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.




FIGURE 1 Prevalence of comorbidities in pooled studies of patients with chronic obstructive pulmonary disease (COPD). Cardiovascular (CV) conditions and comorbidities are highlighted as orange bars and other comorbidities as yellow bars. Data are pooled from numerous studies and comorbidities with a prevalence (calculated as a weighted average based on study sample size) >5% are shown. IHD: ischaemic heart disease; HF: heart failure; AF: atrial fibrillation; CVA: cerebrovascular accident; AAA: abdominal aortic aneurysm; DVT: deep vein thrombosis; BPH: benign prostatic hypertrophy; PH: pulmonary hypertension; GERD: gastroesophageal reflux disease. #: comorbidities with a significant increase in mortality risk compared to patients with COPD without the comorbidity; †: comorbidities with a significantly increased prevalence in patients with COPD compared with the general population. Reproduced and modified with permission from [3].

Patients with comorbid COPD and CVD experience high rates of morbidity, including worse quality of life, dyspnoea and exercise tolerance [8], and a higher risk of hospitalisation for COPD and for CVD [9]. In addition, the presence of CVD or cardiovascular (CV) conditions (such as heart failure (HF), ischaemic heart disease (IHD), diabetes or atrial fibrillation (AF)) increases the risk of frequent exacerbations [10] and mortality [2, 8, 11] (figure 2). Further, COPD exacerbations and lung function decline are associated with increased CV risk and mortality [12, 13]. To minimise the risk of poor outcomes, it is therefore important to ensure that patients with comorbid COPD and CVD are managed effectively. However, drug therapies for COPD could have both beneficial and potential adverse effects on CVD and vice versa.

In the current review we provide a brief overview of key pathophysiological mechanisms, which may help explain comorbid COPD and CVD and inform the rationale for treatment. In the light of the plethora of recent literature considering the CV risks of pharmacotherapy in patients with COPD [14–18] we then provide a synthesis of the research from clinical trials and observational studies to establish the evidence for the main classes of drugs used to treat COPD and CVD. Finally, reflecting on our findings, we make some recommendations for the management of COPD patients with CVD.

### Pathophysiological links between COPD and CVD

The mechanisms which underlie the association between COPD and CVD are not well understood but several processes are thought to be important and may interact with each other [19, 20]. These include




FIGURE 2 Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease [COPD] on mortality. Arrows and associated values indicate the impact of each comorbidity on the mortality risk of patients with COPD *versus* those patients with COPD alone. Where available, the reverse is also shown [the impact of COPD on the mortality risk of patients with each comorbidity *versus* those with the comorbidity alone]. AF: atrial fibrillation; HF: heart failure; HR: hazard ratio; IHD: ischaemic heart disease; PH: pulmonary hypertension. #: HR was not significant after adjustment for confounding risk factors. Reproduced and modified with permission from [3].

lung hyperinflation, hypoxaemia, pulmonary hypertension (PH), systemic inflammation and oxidative stress, exacerbations, shared risk factors and shared genetics (figure 3), as well as COPD phenotype.

Hyperinflation, characterised by abnormally elevated residual gas in the lungs following spontaneous exhalation [21], is a major driver of COPD burden and mortality [1]. It is the cardinal pathophysiological mechanism affecting the mechanics of breathing and can be either static (resulting from destruction of the lung parenchyma and subsequent loss of lung elastic recoil) or dynamic (occurring when a patient inhales




FIGURE 3 Potential interactions between chronic obstructive pulmonary disease [COPD], cardiovascular [CV] risk and cardiovascular disease.

before exhaling fully, trapping air with each additional breath) [21]. Hyperinflation significantly reduces the efficiency of the respiratory muscles [22] and is increasingly recognised as a major cause of dyspnoea (shortness of breath) [23].

Abnormal lung function, including hyperinflation, is also thought to compromise cardiac function through various means [24]. Notably, airflow limitation caused by lung hyperinflation may cause increased pressures in the cardiopulmonary system, right-ventricular dysfunction, impaired left-ventricular filling and reduced cardiac output (QT) [25–29]. Emphysema is associated with static hyperinflation [30] and hyperinflation may therefore be a key risk factor for CVD in patients with emphysema-predominant COPD. In addition, progressive airflow limitation and emphysema in COPD lead to a ventilation/perfusion mismatch that is a key contributor to the development of hypoxaemia, which can be further exacerbated by exercise and sleep disordered breathing [31]. Hypoxaemia in patients with COPD can lead to pulmonary vasoconstriction and vascular remodelling, resulting in right-ventricular diastolic dysfunction [32]. Indeed, PH, common in patients with severe COPD, can lead to right HF, which is in turn associated with left HF [33, 34]. In addition, altered cardiac repolarisation in patients with COPD may be related to hypoxaemia and could increase the risk of ventricular arrhythmias and sudden cardiac death [35].

Chronic or intermittent hypoxia may also increase systemic inflammation, which is known to play a role in the pathogenesis of CVD [36, 37] and has been linked to the development of arterial stiffness which has a strong predictive value for CV events [38]. Markers of pulmonary inflammation (such as surfactant protein D) and of systemic inflammation (such as C-reactive protein (CRP)) are elevated in patients with stable COPD [8, 39–41], while patients with COPD and CVD have higher blood concentrations of inflammatory markers, such as fibrinogen, interleukin (IL)-6 and IL-8, than those without CVD [8]. Moreover, coronary artery calcification scores (a marker of coronary atherosclerosis) correlate with markers of systemic and pulmonary inflammation, such as IL-6, IL-8, surfactant protein D and peripheral blood neutrophil count, in patients with COPD [42]. These findings suggest that COPD is either a systemic inflammatory state or that inflammatory processes spill over from the lungs into the systemic circulation [43], contributing to the development of CVD.

The occurrence of COPD exacerbations has been shown to increase the risk of subsequent CV events in patients with CVD or CV risk factors [44]. This may be related to lung inflammation which is heightened during COPD exacerbations [24]. Furthermore, lower respiratory tract infections, a common cause of COPD exacerbation, are associated with increased inflammatory markers such as fibrinogen and IL-6 which are linked with thrombosis and CV events [12, 45]. High levels of inflammation and oxidative stress that occur during and after an exacerbation may reduce circulating CD34+ cells (which are involved in vascular repair) and increase platelet activation and arterial stiffness [45–49]. Of note, the sudden increase in airway resistance increases that occurs during an exacerbation further limits expiratory flow and lung emptying. Consequently, patients experiencing an exacerbation tend to adopt a rapid, shallow breathing pattern, resulting in a vicious cycle of diminishing lung emptying time and increasing dynamic hyperinflation [22].

The source of CVD risk may be associated with the dominance of either chronic bronchitis or emphysema within the COPD disease profile. The presence of emphysema may reflect accelerated ageing of the lung, which may also result in HF due to downregulation of anti-ageing molecules such as sirtuins [50], while the presence of chronic bronchitis could reflect a distinct inflammatory subtype of COPD requiring specific anti-inflammatory interventions. The genetic background of chronic bronchitis and emphysema also differ, which may influence the processes underlying the association between COPD and CVD [51].

The physiological effects of CVD, for example HF-associated dyspnoea (due to pulmonary oedema) and reduced exercise capacity (due to reduced QT and impaired perfusive and diffusive oxygen transport) [52, 53] may add to the effects of COPD caused by “pulmonary” mechanisms (dyspnoea due to hyperinflation and resulting exercise avoidance and deconditioning [1]). In HF, cardiomegaly may be involved in causing a restrictive lung pattern and reduced alveolar volume [54], with alveolar gas diffusion progressively worsening due to reduction in the lung tissue participating in gas exchange [55]. Ventilatory response to exercise is greater than normal for a given metabolic rate, due to an increase in physiological dead space to tidal volume ratio (driven by high ventilation/perfusion mismatching, increased carbon dioxide production relative to oxygen uptake from lactate buffering and a decrease in partial pressure of carbon dioxide) [56]. The clinical consequences are illustrated in a study in which patients with COPD and IHD had significantly worse health status, dyspnoea and exercise capacity than those without IHD; additionally, although exacerbations were not more frequent, recovery time was longer in those with IHD [57]. CVD is also a leading cause of hospitalisation and mortality in patients with COPD [9].

Although the causal or consequential role of associated systemic inflammation is still not clear in COPD [58, 59], as described earlier, there are a number of mechanisms by which COPD-associated systemic inflammation could contribute to CVD and low-grade systemic inflammation in patients with airflow obstruction has been associated with increased risk of cardiac injury [40]. Systemic inflammation is also a feature of CVD, likely playing a role in its development and progression [60]. While the effect of CVD-associated systemic inflammation on COPD is unknown, a study in COPD patients with and without hepatitis C found a steeper decline in lung function with hepatitis C *versus* controls [61], suggesting an effect on the lungs due to systemic inflammation. Furthermore, risk factors of systemic and vascular inflammation, such as visceral obesity, diabetes and inactivity are also associated with reduced pulmonary function, airway hyper-reactivity and eventually COPD [58], supporting the idea that systemic inflammation associated with CVD may affect COPD.

In summary, many of the pathophysiological mechanisms underlying COPD may increase the risk of CVD and vice versa; however, more studies are needed to provide evidence that the mechanisms uncovered are relevant to the clinical manifestations of these diseases when they occur together.

### Pharmacological management of COPD and CVD

With the close association between COPD and CVD, it is possible that treatments for one condition may influence the other and appropriate treatment of all conditions is therefore essential. Improvements in survival following hospital discharge for acute COPD exacerbation have been attributed to better management of COPD and associated comorbidities, including the use of CV therapies such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs),  $\beta$ -blockers and statins [62]. However, the treatment of CV conditions in patients with COPD is associated with therapeutic challenges, most notably the co-administration of (selective)  $\beta_1$ -blockers and  $\beta_2$ -agonists.  $\beta$ -blockers are widely prescribed in the treatment of CVD and  $\beta$ -agonists represent a cornerstone of COPD treatment; however, the two have opposing pharmacological actions and physicians may be concerned that treatment of one condition may worsen the other [63].

A number of randomised controlled trials (RCTs) and observational studies provide insight into the effect of COPD treatments on CVD and vice versa, although both study types are subject to limitations. For instance, results from observational studies may be affected by lack of blinding of study treatments and confounding bias [64]. Also, observational studies are often reliant upon patient databases, which may lack accuracy (for instance, the definition of COPD and the presence of comorbidities such as asthma) [64–66]. In addition, a number of observational analyses discussed below rely upon prescription data, which may not accurately reflect actual medication intake [65, 66]. Conversely, RCTs are associated with limitations of their own, such as their limited size and duration of exposure, as well as a lack of generalisability to the general COPD population due to stringent inclusion criteria and trial setting [64]. Moreover, RCTs may introduce bias due to the deleterious effect of treatment withdrawal at randomisation, the inclusion of a run-in period, the use of untreated placebo groups and by truncating follow-up at treatment discontinuation [67–69].

### Effects of COPD treatments on CV risk

Among COPD patients, CV causes are the second most common cause of death (following pulmonary causes) [70]. In this section, we discuss the effects of different classes of COPD treatment on CV risk and mortality, followed by the effects of different classes of CV treatment on COPD. Details from key studies [27, 65, 66, 71–124] are summarised in tables 1 and 2.

#### Bronchodilators

There is conflicting evidence regarding the CV safety of bronchodilators. An increased CV risk has been observed with bronchodilators in some studies [72, 76, 84, 125], whereas others found no evidence of increased risk or even some evidence of CV risk reduction [89, 126].

#### $\beta_2$ -agonists

While a systematic review of long-acting  $\beta_2$ -agonists (LABAs), in combination with inhaled corticosteroids (ICS), concluded that ICS/LABA products may have a good CV safety profile in asthma patients [127], evidence for the CV safety of LABAs in COPD is less definitive. LABAs have been associated with an increased risk of CV events, possibly due to stimulation of sympathetic drive [72, 84], which may also increase the risk of arrhythmias and myocardial ischaemia in patients with CVD (particularly HF). In clinical trials,  $\beta_2$ -agonists have been shown to increase heart rate, reduce potassium concentrations and increase the risk of CV events *versus* placebo in patients with obstructive airways disease [72]. Furthermore, studies of Canadian healthcare databases indicate that new use of LABAs is associated with an elevated rate of cardiac arrhythmia in patients with COPD [82, 83]. In addition, a recent analysis of

TABLE 1 Effects of chronic obstructive pulmonary disease (COPD) treatments on cardiovascular (CV) risk

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
<b>β<sub>2</sub>-agonists</b>							
SUISSA (2003) [71]	Population-based, nested case-control (n=12 090)	Follow-up to 1999	Newly diagnosed patients with COPD aged >55 years (identified from the Saskatchewan Health Services databases, 1980–1997)	SABAs	Cases of acute MI occurring during cohort follow-up	1127 evaluable patients identified with fatal or non-fatal acute MI SABA use not associated with increased risk of acute MI (rate ratio for any use: 1.06, 95% CI 0.92–1.23)	No significant increase in risk when analysis is restricted to patients with CV risk factors
SALPETER (2004) [72]	Meta-analysis of randomised and placebo-controlled trials 13 RCTs of single-dose treatment (n=232) 20 trials of longer treatment duration (n=6623)	Mean of 4.7 months (range: 3 days to 1 year)	Patients with obstructive airway disease (COPD or asthma) Mean age 56.6 years (single-dose) and 52.2 years (longer treatment studies)	β <sub>2</sub> -agonists <i>versus</i> placebo	Short-term effect on heart rate and potassium concentrations Long-term effect on adverse CV events	Single-dose β <sub>2</sub> -agonist <i>versus</i> placebo increased heart rate by 9.12 bpm and reduced potassium concentration by 0.36 mmol·L <sup>-1</sup> Longer β <sub>2</sub> -agonist treatment significantly increased risk for CV events (relative risk 2.54, 95% CI 1.59–4.05)	The relative risk for sinus tachycardia was 3.06 (95% CI 1.70–5.50) For all other events, relative risk was 1.66 (95% CI 0.76–3.6)
CAZZOLA (2007) [27]	Randomised, double blind, double dummy (n=20)		COPD and sPAP >20 mmHg (rest)	Salmeterol 50 µg Formoterol 12 µg	Acute haemodynamic response	Mean sPAP significantly decreased <i>versus</i> baseline at 15, 30 and 60 min post-inhalation (p<0.05)	No correlation between maximum increase in FEV <sub>1</sub> and maximum decrease in sPAP after inhalation of salmeterol or formoterol
SANTUS (2015) [73]	Randomised, double blind, placebo controlled, crossover (n=40)		COPD (FEV <sub>1</sub> ≤70% pred; RV ≥135% pred) Absence of CV comorbidities Age 50–85 years	Indacaterol 150 µg <i>versus</i> placebo (1:1)	Effect of reduction of right-ventricular and FRC on right heart systolic/diastolic functional indices	Significant improvements in right-ventricular compliance/cardiac performance with indacaterol <i>versus</i> placebo (p<0.05 after 180 min treatment) as follows: 1) TAPSE: 0.41 mm <i>versus</i> 0.02 mm 2) DT-TR: 11.9 ms <i>versus</i> 3.8 ms 3) ≤Heart rate: -2 bpm <i>versus</i> 0.6 bpm	Indacaterol associated with significant (p<0.05) increases <i>versus</i> placebo in FEV <sub>1</sub> , VC and IC

Continued

TABLE 1 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
<b>Muscarinic antagonists</b>							
KESTEN 2006 [74]	Pooled safety analysis of 19 randomised, double blind, placebo controlled trials (including two asthma trials) (n=7819)		COPD diagnosis with airflow limitation Age ≥40 years Smoking history ≥10 pack-years	Tiotropium 18 µg once daily (n=4435) Placebo (n=3384)	AEs occurring during the study	Tiotropium not associated with increased risk of serious cardiac events <i>versus</i> placebo. Data as follows: 1) CV mortality (relative risk 0.57, 95% CI 0.26–1.26) 2) Cardiac arrest (relative risk 0.90, 95% CI 0.26–3.15) 3) MI (relative risk 0.74, 95% CI 0.26–2.07)	Relative risk of tachycardia with tiotropium <i>versus</i> placebo: 1.68 [95% CI 0.69–4.11]
TRAVERS (2007) [75]	Randomised, double blind, placebo controlled, crossover (n=18)	7–10 day treatment period + 35 day washout period	COPD (FEV <sub>1</sub> ≤65% pred; FRC ≥120% pred; modified baseline dyspnoea index score ≤6)	Tiotropium 18 µg once daily <i>versus</i> placebo	Effect of tiotropium on CV response to exercise	Tiotropium improved cardiac function during exercise <i>versus</i> placebo: 1) Significantly reduced heart rate (105 bpm <i>versus</i> 112 bpm, p<0.05) 2) Higher O <sub>2</sub> pulse (10.9 mL·beat <sup>-1</sup> <i>versus</i> 10.1 mL·beat <sup>-1</sup> , p<0.05) 3) Lower SBP (148 mmHg <i>versus</i> 156 mmHg, p<0.05)	Tiotropium significantly improved measures of dynamic hyperinflation during exercise: IRV was significantly greater with tiotropium <i>versus</i> placebo (0.60 L <i>versus</i> 0.44 L, p<0.05)
SINGH (2008) [76]	Systematic review and meta-analysis (17 RCTs; 12 on tiotropium, 5 on ipratropium) (n=14 783)		COPD of any severity	Tiotropium or ipratropium (n=7472) <i>versus</i> control (placebo/active control) (n=7311)	Composite of non-fatal MI, non-fatal stroke and CV death	Tiotropium or ipratropium significantly increased risk of CV death, MI or stroke <i>versus</i> control (1.8% <i>versus</i> 1.2%; relative risk 1.58 [95% CI 1.21–2.06], p<0.001)	Tiotropium or ipratropium did not significantly increase risk of all-cause mortality <i>versus</i> control (2.0% <i>versus</i> 1.6%; relative risk 1.26 [95% CI 0.99–1.61], p=0.06)
RODRIGO (2009) [77]	Systematic review and meta-analysis (19 RCTs) (n=18111)	7 trials (28–48 months) 12 trials (8 weeks–6 months)	Patients with COPD (average baseline FEV <sub>1</sub> : 41% pred normal) Mean age 64.8 years	Tiotropium <i>versus</i> placebo (n=15 <sup>#</sup> ), SFC (n=2 <sup>#</sup> ), salmeterol (n=1 <sup>#</sup> ), salmeterol/placebo (n=1 <sup>#</sup> )	Composite of MACE, CV mortality and non-fatal MI or stroke	No difference in incidence of MACE <i>versus</i> control groups (relative risk 0.96, 95% CI 0.82–1.12)	Compared with control groups, tiotropium did not significantly increase risk of: 1) CV death (relative risk 0.93, 95% CI 0.73–1.20) 2) Non-fatal MI (relative risk 0.84, 95% CI 0.64–1.09) 3) Non-fatal stroke (relative risk 1.04, 95% CI 0.78–1.39)

Continued

TABLE 1 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
CELLI (2009, UPLIFT) [78]	Multicentre, randomised, double blind, placebo-controlled, parallel group (n=5993) Mortality analysis	4 years	Patients aged >40 years with COPD (post-bronchodilator FEV <sub>1</sub> ≤70% pred normal; FEV <sub>1</sub> /FVC ≤70%)	Tiotropium (n=2987) Placebo (n=3006)	Effect of tiotropium on survival	Reduced risk of cardiac mortality with tiotropium <i>versus</i> placebo (HR 0.86, 95% CI 0.75–0.99)	Reduced risk of all-cause mortality for tiotropium <i>versus</i> placebo (HR 0.84 [95% CI 0.73–0.97], p=0.016)
NOJIRI 2012 [79]	Single-centre, prospective, pilot (n=21)	12 weeks	Patients with COPD (FEV <sub>1</sub> /FVC <0.70) and prior (≥1 year) pulmonary resection for lung cancer ECOG status 1 >20 pack-year smoking history	Tiotropium 18 µg once daily	Pulmonary function and left-ventricular diastolic dysfunction (E/e' ratio <sup>¶</sup> )	Significant improvements after tiotropium ( <i>versus</i> before tiotropium) in: 1) FEV <sub>1</sub> (1.84 L <i>versus</i> 1.60 L, p<0.001) 2) E/e' ratio (7.59 <i>versus</i> 8.97, p<0.001)	No significant differences before/after tiotropium in BP, heart rate, FVC, left-ventricular mass and LVEF Significant improvement in PASP <i>versus</i> before tiotropium (33.0 mmHg <i>versus</i> 38.5 mmHg, p<0.01)
PEPIN (2014) [80]	Multicentre, randomised, double dummy, parallel group, blinded (n=257)	12 weeks	COPD patients aged ≥40 years Smoking history ≥10 pack-years Post-bronchodilator FEV <sub>1</sub> ≤70% pred normal FEV <sub>1</sub> /FVC ≤0.70 aPWV ≥11 m·s <sup>-1</sup>	Tiotropium 18 µg once daily (n=130) <i>versus</i> fluticasone furoate/vilanterol combination 100 µg/25 µg once daily (n=127)	Change from baseline in arterial stiffness (aPWV)* at 12 weeks	At 12 weeks there was a comparable reduction from baseline in aPWV with tiotropium (–1.118 m·s <sup>-1</sup> ) and fluticasone furoate/vilanterol combination (–0.859 m·s <sup>-1</sup> , p=ns)	No significant differences between tiotropium and fluticasone furoate/vilanterol combination for change from baseline in trough FEV <sub>1</sub> (0.080 L <i>versus</i> 0.117 L) or IC (0.019 L <i>versus</i> 0.089 L)
SUISSA (2017) [65]	UK observational, population-based prior ICS-matched cohort analysis (primary care, CPRD) (n=115 397, base cohort (new users of a long-acting bronchodilator); n=70 550, sub-cohort (linked to HES database))	1 year	New users of long-acting bronchodilators (LABA or tiotropium) for COPD Aged >55 years ≥2 years medical history First LABA/tiotropium prescription on/after September 25, 2003	Full cohort (matched by propensity score): tiotropium (n=26 442), LABA (n=26 442) HES sub-cohort: tiotropium (n=15 427), LABA (n=15 427)	Incidence of acute MI, stroke, HF (full cohort) and incidence of arrhythmia and pneumonia (HES sub-cohort) following 1 year of treatment with tiotropium <i>versus</i> LABA	No difference between tiotropium <i>versus</i> LABA in CV events, as follows: 1) Acute MI: HR 1.10 (95% CI 0.88–1.38) 2) Stroke: HR 1.02 (95% CI 0.78–1.34) 3) Heart failure: HR 0.90 (95% CI 0.79–1.02) 4) Arrhythmia: HR 0.81 (95% CI 0.60–1.09)	Risk of pneumonia significantly reduced with tiotropium <i>versus</i> LABA (HR 0.81, 95% CI 0.72–0.92)
<b>β<sub>2</sub>-agonists and muscarinic antagonists</b>							
BERTON (2010) [81]	Double-blind, placebo-controlled, crossover (n=12)		Moderate-to-severe COPD (FEV <sub>1</sub> /FVC <0.7; post-bronchodilator FEV <sub>1</sub> <60% pred) Resting P <sub>aO<sub>2</sub></sub> >60 mmHg	Salbutamol 120 µg + ipratropium 20 µg/actuation <i>versus</i> placebo	Key determinants of O <sub>2</sub> delivery and uptake during high-intensity, constant work rate cycling exercise	Compared with placebo, bronchodilators accelerated central haemodynamic response at exercise onset, as follows: 1) t <sub>1/2</sub> QT: 75.9±10.3 s <i>versus</i> 58.9±18.9 s (p=0.02)	Bronchodilators led to lung deflation and increased exercise tolerance <i>versus</i> placebo (454±131 s <i>versus</i> 321±140 s; p<0.05)

Continued



TABLE 1 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
WILCHESKY (2012–part 1) [82]	Retrospective, cohort (healthcare databases, Province of Saskatchewan, Canada) (n= 6018)		COPD patients aged ≥55 years Newly treated COPD (three or more prescriptions for a bronchodilator, on two different dates, within any 1-year period)	LABA SABA Methylxanthines Ipratropium bromide	Rate of cardiac arrhythmias	2) t <sub>1/2</sub> heart rate: 78.2±13.0 s <i>versus</i> 62.5±15.5 s (p=0.03) 3) t <sub>1/2</sub> SV: 51.0±8.1 s <i>versus</i> 40.6±10.3 s (p=0.02) Rate of arrhythmia increased with new use of: 1) ipratropium (relative risk 2.4, 95% CI 1.4–4.0) 2) LABA (relative risk 4.5, 95% CI 1.4–14.4) Rate of arrhythmia was not increased with new use of: 1) SABA (relative risk 0.9, 95% CI 0.5–1.6) 2) Methylxanthines (relative risk 1.6, 95% CI 0.7–3.7)	
WILCHESKY (2012–part 2) [83]	Retrospective, cohort (healthcare databases, Quebec, Canada) (n=76 661)		COPD patients aged ≥67 years Newly treated COPD (three or more prescriptions for a bronchodilator, on two different dates between January 01, 1990 and December 31, 2002)	LABA SABA Methylxanthines Ipratropium bromide	Rate of cardiac arrhythmias	Rate of arrhythmia increased with new use of: 1) SABA (relative risk 1.27, 95% CI 1.03–1.57) 2) LABA (relative risk 1.47, 95% CI 1.01–2.15) Rate of arrhythmia slightly (not significantly) increased with new use of: 1) ipratropium bromide (relative risk 1.23, 95% CI 0.95–1.57) 2) Methylxanthines (relative risk 1.28, 95% CI 0.93–1.77)	
GERSHON (2013) [84]	Population-based, nested case–control analysis of a retrospective study (n=191 005)		COPD patients aged ≥66 years Receiving treatment (September 2003–March 2009) 53 532 had a CV event 26 628 matched to control <sup>§</sup>	LABA LAMA	Hospitalisation or ED visit for a CV event	New users of LABAs and LAMAs more likely <i>versus</i> non-users to have a CV-related hospitalisation/ED visit LABAs: OR 1.31 [95% CI 1.12–1.52], p<0.001 LAMAs: OR 1.14 [95% CI 1.01–1.28], p=0.03	No significant difference in CV events between LABAs and LAMAs (OR 1.15 [95% CI 0.95–1.38], p=0.16)

Continued

TABLE 1 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
WANG [2018] [123]	Nested case-control study (healthcare database, Taiwan) (n=284 229)		COPD patients aged $\geq 40$ years LABA-LAMA naïve 37719 had a CV event Matched with 146 139 randomly selected controls	LABA LAMA	Inpatient or ED visit for CAD, HF, ischaemic stroke or arrhythmia	New LABA and LAMA use were associated with an increased risk of a CV event within 30 days (OR 1.50 [95% CI 1.35–1.67], $p < 0.001$ and OR 1.52 [95% CI 1.28–1.80], $p < 0.001$ , respectively). The risk was absent, or even reduced, with prevalent use	No difference in risk was observed between individual LABA agents, LAMA dosage forms, or concomitant COPD regimens
<b>LABA/LAMA combinations</b>							
SUISSA [2017] [66]	UK observational, population-based cohort analysis (primary care, CPRD) (n=463 899, base cohort) 31 174 patients on combined bronchodilator therapy matched to 31 174 patients on bronchodilator monotherapy	1 year	New users of long-acting bronchodilators (LABA or tiotropium) for COPD Aged $> 55$ years $\geq 2$ years medical history First LABA/tiotropium prescription on/after September 25, 2002	LABA/tiotropium initiation + second long-acting bronchodilator (n=31 174) Bronchodilator monotherapy (n=31 174)	Incidence of acute MI, stroke, HF and arrhythmia following 1 year of treatment	Combination of two long-acting bronchodilators was not associated with increased risk of: 1) Acute MI (HR 1.12, 95% CI 0.92–1.37) 2) Stroke (HR 0.87, 95% CI 0.69–1.10) 3) Arrhythmia (HR 1.05, 95% CI 0.81–1.36)	Two long-acting bronchodilators in combination were associated with increased risk of HF (HR 1.16, 95% CI 1.03–1.30)
SAMP [2017] [85]	Retrospective, observational cohort (using health insurance claims data) (n=19 078 matched patients)		Patients with COPD initiating LABA/LAMA or ICS/LABA	LABA/LAMA (n=3844) ICS/LABA (n=15 234)	CCV outcomes: hospitalisations for ACS, HF, cardiac dysrhythmia, stroke, or TIA	LABA/LAMA treatment was associated with fewer CV events <i>versus</i> ICS/LABA treatment (HR 0.794, 95% CI 0.623–0.997)	No difference between treatments in cerebrovascular events (HR 1.166, 95% CI 0.653–1.959)
HOHLFELD [2017] [86]	Randomised, double-blind, single centre, placebo-controlled, two period, crossover (n=62)		Patients with COPD and increased RV ( $> 135\%$ predicted) without CVD	Indacaterol/ glycopyrronium 110 $\mu\text{g}/50 \mu\text{g}$ once daily Placebo	Change in LVEDV measured with MRI on day 14	Compared with placebo, indacaterol/ glycopyrronium resulted in a significant increase in LVEDV (10.27 mL, $p < 0.0001$ ) and QT (0.337 L $\cdot\text{min}^{-1}$ , $p = 0.0032$ )	Compared with placebo, indacaterol/ glycopyrronium was associated with: 1) Improved lung function (peak FEV <sub>1</sub> increased by 0.42 L, $p < 0.0001$ ) 2) Reduced lung hyperinflation (RV $-0.75$ L, $p < 0.0001$ )
<b>ICS and ICS/LABA combinations</b>							
HUIART [2005] [87]	Nested case-control analysis (health services databases, Saskatchewan, Canada) (n=5648)	Follow-up until first MI	Patients $\geq 55$ years with new-onset COPD who had not received any bronchodilator, anti-asthma drug or	ICS	First fatal or non-fatal acute MI	Results based on 371 cases with first acute MI matched to 1864 controls Low-dose ICS (50–200 $\mu\text{g}\cdot\text{day}^{-1}$ )	Overall, current use of ICS was not associated with a significant decrease in risk of acute MI (rate ratio 0.82, 95% CI 0.57–1.16)

Continued

TABLE 1 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
LoKE (2010) [88]	Systematic review of 23 RCTs (n=23396) and 12 observational studies	RCTs ≥24 weeks	nasal/ICS in the previous 5 years Patients with COPD of any severity	ICS <i>versus</i> placebo or ICS/LABA <i>versus</i> LABA	Risk of fatal and non-fatal MI and CV death	significantly reduced risk of acute MI by 32% (rate ratio 0.68, 95% CI 0.47–0.99) Findings from RCTs indicated that ICS were not associated with significantly reduced risk of MI (relative risk 0.95, 95% CI 0.73–1.23), CV death (relative risk 1.02, 95% CI 0.81–1.27) or mortality (relative risk 0.96, 95% CI 0.86–1.07)	Findings from observational studies indicated that ICS use was associated with a significant reduction in CV death (two studies: relative risk 0.79 [95% CI 0.72–0.86], p<0.0001) and mortality (11 studies: relative risk 0.78 [95% CI 0.75–0.80], p<0.0001)
CALVERLEY (2010, TORCH) [89]	Multicentre, randomised, double-blind, placebo-controlled, parallel group ( <i>post hoc</i> analysis) (n=6184)	3 years	Patients (current/former smokers) with COPD (pre-bronchodilator FEV <sub>1</sub> <60% pred and FEV <sub>1</sub> /FVC ≤0.70) Aged 40–80 years	Salmeterol/fluticasone propionate combination 50 µg/500 µg (n=1546) Salmeterol 50 µg (n=1542) Fluticasone propionate 500 µg (n=1552) Placebo (n=1544) (all twice daily)	CV AEs and SAEs	The probability of patients having a CV AE by 3 years was lowest for salmeterol/fluticasone propionate combination (20.8%) <i>versus</i> placebo (24.2%), salmeterol (22.7%) and fluticasone propionate (24.3%)	Treatment with salmeterol/fluticasone propionate combination was associated with a significant reduction <i>versus</i> placebo in probability of a CV AE by 3 years in patients receiving CV therapy at baseline (27.9% <i>versus</i> 33.5%, respectively; p<0.05)
DRANSFIELD (2011) [90]	Multicentre, randomised, double-blind, placebo-controlled (n=249)	12 weeks	Patients with COPD (post-bronchodilator FEV <sub>1</sub> <80% pred and FEV <sub>1</sub> /FVC ratio ≤0.70) Aged ≥50 years Smoking history of ≥10 pack-years	Salmeterol/fluticasone propionate combination 50 µg/250 µg twice daily (n=123) Placebo (n=126) (Both arms received open label tiotropium 18 µg once daily for 4 weeks after a 12 week treatment period)	aPWV change from baseline at 12 weeks	For patients that remained on treatment for 12 weeks (n=96 in each group), salmeterol/fluticasone propionate combination was associated with a significant reduction in aPWV <i>versus</i> placebo (−0.49 m·s <sup>−1</sup> , p=0.045)	No significant changes in aPWV for salmeterol/fluticasone propionate combination + tiotropium <i>versus</i> tiotropium from 12–16 weeks (mean change 0.18 m·s <sup>−1</sup> )

Continued

TABLE 1 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
STONE (2016) [91]	Single-centre, randomised, double-blind, placebo-controlled, crossover (n=45)	Two 7-day treatment periods separated by a 7±2-day washout period	COPD (FEV <sub>1</sub> <70% pred) Smoking history ≥15 pack-years Aged >40 years MRC score >1 Lung hyperinflation (RV >120% pred) which improved ≥7.5% after salbutamol	Fluticasone furoate/vilanterol combination 100 µg/25 µg once daily Placebo	Change in RVEDVI from baseline <i>versus</i> placebo after 7 days treatment (maximum 14 days)	Mean increase in change from baseline in RVEDVI of 5.8 mL·m <sup>-2</sup> (95% CI 2.74–8.91), p<0.001 <i>versus</i> placebo	Improved lung hyperinflation and airflow limitation from baseline with fluticasone furoate/vilanterol combination relative to placebo, as follows: 1) RV: 429 mL reduction (p<0.001) 2) Increased IC, IC/TLC, FEV <sub>1</sub> and FVC (261 mL, 4.6%, 220 mL and 350 mL, respectively; all p<0.001)
VESTBO (2016, SUMMIT) [92]	Multicentre, randomised, double-blind, placebo-controlled, parallel group, event-driven (n=16 485)	Maximum follow-up was 4 years	COPD (post-bronchodilator FEV <sub>1</sub> 50–70% pred and FEV <sub>1</sub> /FVC ≤0.70) Smoking history ≥10 pack-years mMRC dyspnoea scale ≥2 History/increased risk of CVD	Fluticasone furoate/vilanterol combination 100 µg/25 µg once daily (n=4121) Fluticasone furoate 100 µg once daily (n=4135) Vilanterol 25 µg once daily (n=4118) Placebo (n=4111)	All-cause mortality	All-cause mortality did not differ significantly between fluticasone furoate/vilanterol combination and placebo (HR 0.88 (95% CI 0.74–1.04); 12% relative reduction, p=0.137) or components	Fluticasone furoate/vilanterol combination had no effect on composite CV events (CV death, MI, stroke, unstable angina, TIA) compared with placebo (HR 0.93, 95% CI 0.75–1.14)
BHATT (2017) [93]	Multicentre, randomised, double-blind, parallel group, placebo-controlled (stratified by COPD exacerbation history) (n=430)	24 weeks	Patients aged ≥40 years with a history of COPD ≥10 pack-year smoking history FEV <sub>1</sub> /FVC ≤0.70 Post-bronchodilator FEV <sub>1</sub> ≤70% pred aPWV ≥11 m·s <sup>-1</sup>	Fluticasone furoate/vilanterol combination 100 µg/25 µg once daily (n=135) Vilanterol 25 µg once daily (n=154) Placebo (n=141)	Change from baseline in aPWV after 24 weeks with fluticasone furoate/vilanterol combination <i>versus</i> placebo	No significant difference in mean change from baseline in aPWV at 24 weeks with fluticasone furoate/vilanterol combination (–1.75 m·s <sup>-1</sup> ) <i>versus</i> placebo (–1.97 m·s <sup>-1</sup> )	<i>Post-hoc</i> analysis indicated a greater proportion of responders <sup>f</sup> in the fluticasone furoate/vilanterol combination <i>versus</i> placebo groups when withdrawn patients were classified as non-responders (50% <i>versus</i> 36%, respectively)

Continued

TABLE 1 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
<b>Other COPD pharmacological treatments</b>							
SUISSA (1996) [94]	Population-based cohort from Saskatchewan, Canada (n=12301)		Patients with asthma aged 5–54 years	Theophylline and $\beta$ -agonists <i>versus</i> control	Identified 30 CV deaths in which acute asthma did not appear to be a contributing factor	Rate of CV death was greater with theophylline (rate ratio 2.7, 95% CI 1.2–6.1) and $\beta$ -agonists administered orally or by nebuliser (rate ratio 2.4, 95% CI 1.0–5.4)	Rate of CV death was not greater with $\beta$ -agonists administered by MDI (rate ratio 1.2, 95% CI 0.5–2.7)
HUERTA (2005) [95]	Nested case-control (population-based cohort, UK General Practice Research Database after January 01, 1994) (n=5710)		Patients aged 10–79 years with asthma or COPD (710 cases and 5000 controls)	Theophylline (and other therapies: $\beta$ -agonists, oral steroids, ICS)	Rhythm disorders	Short-term theophylline use was weakly associated with: 1) Arrhythmia (relative risk 1.8, 95% CI 1.0–3.3) 2) AF (relative risk 1.8, 95% CI 0.9–3.7)	Short-term theophylline use was associated with supraventricular tachycardia (relative risk 4.0, 95% CI 0.9–18.1)
WHITE (2013) [96]	Pooled analysis of 14 intermediate and long-term trials (n=12 054)	Range: 12–52 weeks	Patients with moderate-to-very-severe COPD	Roflumilast (n=6563) Placebo (n=5491)	MACE (CV death, non-fatal MI and stroke)	MACE composite rate was significantly lower with roflumilast <i>versus</i> placebo (HR 0.65 [95% CI 0.45–0.93], p=0.019)	MACE experienced by 14.3/1000 patient-years (roflumilast) and by 22.3/1000 patient-years (placebo)

ACS: acute coronary syndrome; AE: adverse event; AF: atrial fibrillation; aPWV: aortic pulse wave velocity; BP: blood pressure; CAD: coronary artery disease; CCV: cardiovascular and cerebrovascular; CPRD: Clinical Practice Research Datalink; CVD: cardiovascular disease; DT-TR: tricuspid E-wave deceleration time; ECOG: Eastern Cooperative Oncology Group; ED: emergency department; E/e': ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annual movement velocity; FEV<sub>1</sub>: forced expiratory volume in 1 s; FRC: functional residual capacity; FVC: forced vital capacity; HES: hospital episode statistics; HF: heart failure; HR: hazard ratio; IC: inspiratory capacity; ICS: inhaled corticosteroid; IRV: inspiratory reserve volume; LABA: long-acting  $\beta_2$ -agonist; LAMA: long-acting muscarinic antagonist; LVEDV: left-ventricular end-diastolic volume; LVEF: left-ventricular ejection fraction; MACE: major adverse cardiovascular event; MDI: metered dose inhaler; MI: myocardial infarction; mMRC: modified Medical Research Council; MRI: magnetic resonance imaging; NS: not significant; OR: odds ratio;  $P_{aO_2}$ : arterial oxygen tension; PASP: pulmonary arterial systolic pressure; QT: cardiac output; RCT: randomised controlled trial; RVEDVI: right-ventricular end-diastolic volume index; RV: residual volume; SABA: short-acting  $\beta_2$ -agonist; SAE: serious adverse event; SFC: salmeterol/fluticasone combination; SBP: systolic blood pressure; sPAP: systolic pulmonary arterial pressure; SV: stroke volume; TAPSE: tricuspid annular plane systolic excursion; TIA: transient ischaemic attack; TLC: total lung capacity; VC: vital capacity. <sup>#</sup>: number of studies; <sup>†</sup>: increases with elevation of left-ventricular filling pressure that occurs due to impaired left-ventricular diastolic function; <sup>\*</sup>: marker of CV risk; <sup>§</sup>: for each case, one control was randomly selected, matched for age ( $\pm 1$  year), sex, duration of COPD, HF and history of hospitalisation for ACS, HF, ischaemic stroke, cardiac arrhythmia and acute respiratory disease (acute exacerbation of COPD, pneumonia, influenza, or acute bronchitis); <sup>‡</sup>: patients with aPWV reduction from baseline of  $\geq 1$  m·s<sup>-1</sup> on day 168.

TABLE 2 Effects of cardiovascular (CV) treatments on chronic obstructive pulmonary disease (COPD)

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
<b>β-blockers</b>							
DRANSFIELD (2008) [97]	Retrospective, cohort (University of Alabama Hospital) (n=825)		Discharge or death summaries indicated primary diagnosis of AECOPD or primary diagnosis of ARF and secondary diagnosis of AECOPD	Users of β-blockers (n=142) Non-users (n=683)	In-hospital mortality	β-blocker use was associated with a reduction in mortality (OR 0.39, 95% CI 0.14–0.99)  A significant association was observed between daily β-blocker doses and mortality (OR 0.31, 95% CI 0.12–0.80)	SABA use was also associated with a reduction in mortality (OR 0.39, 95% CI 0.14–0.99)
RUTTEN (2010; Utrecht GP Network Database) [98]	Observational, cohort (n=2230)		Individuals aged ≥45 years with an incident or prevalent diagnosis of COPD	β-blockers	All-cause mortality First COPD exacerbation	β-blocker use was associated with: 1) A reduction in mortality (HR 0.68, 95% CI 0.56–0.83) 2) A reduction in exacerbations (HR 0.71, 95% CI 0.60–0.83)	Subgroup analyses revealed that patients with COPD but without overt CVD had similar results
SHORT (2011) [99]	Retrospective, cohort (NHS Tayside Respiratory Disease Information System) (n=5977)		Diagnosis of COPD (GOLD guidelines)	Respiratory and CV drugs	Mortality COPD-related hospital admissions	β-blocker use was associated with: 1) A 22% reduction in all-cause mortality <i>versus</i> no β-blocker use 2) Reduction in mortality from MI (HR 0.67, 95% CI 0.41–1.10) and COPD (HR 0.88, 95% CI 0.32–2.38) 3) Reduced risk of respiratory-related hospital admissions (HR 0.31, 95% CI 0.22–0.44)	
STEFAN (2012) [100]	Retrospective, cohort (Perspective Inpatient Administrative Database [Premier Inc, Charlotte, NC, USA], 404 hospitals) (n=35 082)		Individuals aged ≥40 years with a principal diagnosis of AECOPD, or a principal diagnosis of respiratory failure and a secondary diagnosis of AECOPD or emphysema, and with a secondary diagnosis of IHD or HF	β-blockers Treatment with inhaled β <sub>2</sub> -agonists and systemic corticosteroids on the first or second day of the hospitalisation	In-hospital mortality	No association between β-blocker therapy and: 1) In-hospital mortality (OR 0.88, 95% CI 0.71–1.09) 2) 30-day readmission (OR 0.96, 95% CI 0.89–1.03) 3) Late mechanical ventilation (OR 0.98, 95% CI 0.77–1.24)	25% increased odds of 30-day readmission (OR 1.25, 95% CI 1.08–1.44) with nonselective β-blocker <i>versus</i> β <sub>1</sub> -selective β-blocker

Continued

TABLE 2 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
Du (2014) [101]	Meta-analysis (15 observational, cohort studies) (n=121 956)	1–7.2 years	Individuals with COPD	β-blockers	Mortality	β-blocker use was associated with: 1) A reduction in COPD exacerbations (rate ratio 0.63, 95% CI 0.57–0.71) 2) A reduction in the risk of overall mortality (rate ratio 0.72, 95% CI 0.63–0.83)	
PUENTE-MAESTU (2014) [102]	Analytical, cross-sectional (n=256)		Individuals with previous COPD diagnosis and CHF/CAD diagnosis ≥1 year prior to baseline who meet the criteria for β-blocker treatment with no contraindications	β-blocker	Lung function ECG LVEF Haemoglobin concentrations Heart rate Exacerbations Hospital admissions CAT Comorbidities	β-blocker use was associated with: 1) Fewer COPD patients experiencing exacerbations requiring ER visits (36.9% versus 58.8% among patients without β-blockers, p<0.000) 2) Fewer COPD patients experiencing ≥2 exacerbations or ER visits (38.8% versus 58.8% among patients without β-blockers, p<0.000)	
BHATT (2016; follow-up of the COPDGene cohort) [103]	Prospective, follow-up (n=3464)	2.1 years median follow-up	Individuals diagnosed with GOLD stage 2 to 4 COPD	β-blocker CCB ACEI/ARB	Exacerbation rate (total and severe)	β-blocker use was associated with a reduction in the rate of total exacerbations (IRR 0.73 (95% CI 0.60–0.90), p=0.003) and severe exacerbations (IRR 0.67 (95% CI 0.48–0.93), p=0.016) In individuals with GOLD stage 3 and 4, β-blocker use was associated with a reduction in the rate of total exacerbations (IRR 0.33 (95% CI 0.19–0.58), p<0.001) and severe exacerbations (IRR 0.35 (95% CI 0.16–0.76), p=0.008)	
KEY (2017) [104]	Cohort, cross-over (n=48)		Individuals were aged ≥18 years and able to perform a cardiopulmonary exercise test	β-blocker	Lung function	β-blocker use led to a small reduction in FEV <sub>1</sub> compared with non-use	

Continued

TABLE 2 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
<b>RAAS blockers (ACEIs, ARBs)</b>							
KANAZAWA (2003) [105]	Randomised, double-blind, placebo-controlled, crossover, pilot (n=36)		Males with COPD (ACE genotypes II (n=13), ID (n=11), DD (n=12))	Captopril 25 mg·day <sup>-1</sup> Placebo	Pulmonary haemodynamics (mean PAP, PVR, lactate concentration and P <sub>vO<sub>2</sub></sub> )	Mean PAP, PVR and lactate concentration after exercise were lower for captopril than placebo in patients with the genotypes II or ID	P <sub>vO<sub>2</sub></sub> after exercise was higher with captopril <i>versus</i> placebo in patients with genotype II
ANDREAS (2006) [106]	Randomised, double-blind, placebo-controlled (n=60)	4 months	Patients with COPD (FEV <sub>1</sub> <50% pred) Aged 30–80 years	Irbesartan 150 mg·day <sup>-1</sup> (increased to 300 mg·day <sup>-1</sup> after 4 weeks) (n=30) Placebo (n=30)	Lung function (P <sub>lmax</sub> )	Irbesartan did not affect P <sub>lmax</sub> (baseline: 4.8 kPa; 4 months: 4.5 kPa)	Irbesartan reduced: 1) TLC (baseline: 119.7% pred; 4 months: 113.7% pred; p=0.01) 2) Haematocrit (from 46.4% to 43.9%, p<0.0001 <i>versus</i> placebo)
PARIKH (2017) [124]	Population-based cohort study (as part of the Multi-Ethnic Study of Atherosclerosis) (n=4472)	9.3 years median follow-up	Participants aged 45–84 years from the general population (3% had emphysema at baseline)	ACEIs ARBs	Percent emphysema (percentage of lung regions less than –950 Hounsfield units on CT scans)	Higher doses of ACE or ARB were independently associated with a slower change in percent emphysema (p=0.03). Over 10 years, the predicted mean increase in participants who used maximum doses of ARBs or ACEIs was 0.06 percentage points <i>versus</i> 0.66 percentage points in those who did not take ARBs or ACEIs (p=0.01)	The findings were of greatest magnitude among former smokers (p<0.001)
LAI (2018) [122]	Population-based cohort (Taiwan National Health Insurance Database) (n=12 452)	6–11 year follow-up	Patients with COPD aged ≥40 years who received prescriptions for an ACEI or ARB for >90 days between 2000 and 2005 Allocated to ACEI (n=6226) and ARB (n=6226) cohorts	ACEIs ARBs	Pneumonia Severe exacerbations (COPD-related hospitalisation or ER visit) Mortality	Patients treated with ACEIs had significantly higher rates of severe COPD exacerbations (adjusted rate ratio 1.22, 95% CI 1.15–1.29) and a higher risk of pneumonia (adjusted HR 1.22, 95% CI 1.15–1.29) than those in the ARB group	ARBs were also associated with a lower risk of pneumonia requiring mechanical ventilation (adjusted HR 1.35, 95% CI 1.24–1.47) and of mortality (adjusted HR 1.33, 95% CI 1.26–1.42)

Continued



TABLE 2 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
<b>Statins</b>							
MANCINI (2006) [107]	Retrospective, time-matched nested case-control (Quebec Linked Databases) (n=19 720)		Two cohorts (aged ≥65 years) as follows: 1) Revascularised patients with high CV risk (n=946 cases; n=18 774 controls) 2) General population of NSAID users without previous MI (n=4907 cases; n=98 097 controls)	Statins ACEIs ARBs	COPD hospitalisation MI Mortality	Statin use was associated with reduced risk for COPD hospitalisation (p=0.0091) and with the combined use of statins and ACEIs or ARBs (p=0.0012) Risk ratios for MI were reduced by all three drug classes, particularly by the combination of statins with ACEIs or ARBs (p<0.0001) Death risk ratios were reduced by ARBs (p=0.0010), statins (p<0.0001) and statins with ACEIs or ARBs (p<0.0001)	Similar benefits were observed when steroid users were included in the analysis
ALEXEEFF (2007; Veterans Administration normative study) [108]	Longitudinal (n=803)	10 year follow-up	Elderly men with no prior known medical conditions	Statins	Lung function (FEV <sub>1</sub> , FVC)	Estimated decline in FEV <sub>1</sub> was lower in patients using statins than those not using statins (10.9 mL·year <sup>-1</sup> versus 23.9 mL·year <sup>-1</sup> , respectively) Estimated decline in FVC was lower in patients using statins than those not using statins (14 mL·year <sup>-1</sup> versus 36.2 mL·year <sup>-1</sup> , respectively)	There was a significant three-way association between time since first visit, statin use and smoking status (p<0.001)
LEE (2009) [109]	Randomised, double-blind, parallel group (n=53)	6 months	Patients with COPD and PH aged 40–80 years FEV <sub>1</sub> <80% pred FEV <sub>1</sub> /FVC <70%	Pravastatin 40 mg·day <sup>-1</sup> (n=27) Placebo (n=26)	Change in exercise time from baseline to 6 months	Exercise time significantly increased from baseline with pravastatin (52% at 6 months, from 660 s to 1006 s; p<0.0001)	Pravastatin was associated with less dyspnoea after exercise versus placebo (Borg dyspnoea score decreased from 6.7 at baseline to 3.86 at 6 months with pravastatin versus 6.9 to 6.8 with placebo; p<0.05)

Continued

TABLE 2 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
MORTENSEN [2009] [110]	Retrospective national cohort (VA administrative data) (n=11 212)		Patients (98% male) aged >65 years hospitalised with COPD exacerbation and received one or more respiratory medications <sup>#</sup> within 90 days of presentation	Users of statins or ACEIs/ARBs (n=4711) Non-users (n=6501)	90-day mortality	Statin use associated with significantly reduced 90-day mortality (OR 0.51, 95% CI 0.40–0.64)	ACEI/ARB use associated with significantly reduced 90-day mortality (OR 0.55, 95% CI 0.46–0.66)
BARTZIOKAS [2011] [111]	Prospective follow-up (n=245)	12 months	Patients with COPD admitted to hospital for COPD exacerbations	Statins	30-day or 1-year mortality	Statins had no effect on 30-day or 1-year mortality	Statins were associated with a lower risk for COPD exacerbations (HR 0.656, 95% CI 0.454–0.946) and severe exacerbations (HR 0.608, 95% CI 0.381–0.972)
HUANG [2011] [112]	Population-based cohort (Taiwan National Health Insurance Database) (n=18 721)	4.58 year mean follow-up	Patients newly diagnosed with COPD (median age 64 years) receiving statins for hyperlipidaemia	Statins (n=6252) Control (n=12 469; matched for age, sex and COPD treatment (non-statin users))	Hospitalisation for COPD	Fewer patients in the statin group (n=508, 8.1%) were hospitalised for COPD exacerbation <i>versus</i> the control group (n=1324, 10.6%; p<0.001)	Statin use was associated with decreased risk of COPD hospitalisation (HR 0.66 [95% CI 0.60–0.74], p<0.001)
BANDO [2012; Japan] [113]	Observational, cross-sectional (n=853)		Outpatients ≥40 years who regularly visited a primary healthcare facility	Statins	Lung function	The prevalence of airflow limitation was lower among patients with a history of statin use than those who had not used statins (2.3% <i>versus</i> 10.5%, respectively) Statin use was not significantly associated with a lower prevalence of airflow limitation	Airflow limitation was not observed in patients with a history of smoking who had used statins
WANG [2013] [114]	Retrospective nested case-control (nationwide health insurance claims database, Taiwan) (n=14 316)		Patients with COPD hospitalised for COPD exacerbations (n=1584) matched to 5950 controls	Statins	COPD exacerbation	Current use of statins associated with a 40% decreased risk of COPD exacerbation (OR 0.60, 95% CI 0.44–0.81)	Statins reduced risk of COPD exacerbations in a dose-dependent manner (medium average daily dose: OR 0.60, 95% CI 0.41–0.89; high daily dose: OR 0.33, 95% CI 0.14–0.73)

Continued

TABLE 2 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
LAHOUSSE (2013; Rotterdam Study) [115]	Nested case-control (n=7983)		363 patients with COPD who died during follow-up <i>versus</i> 2345 age-/sex-matched COPD controls	Statins	Mortality	Long-term statin use (>2 years) was associated with a 39% decreased risk of death	Long-term statin use was associated with 78% reduced mortality with hsCRP >3 mg·L <sup>-1</sup> ( <i>versus</i> 21% reduction for hsCRP ≤3 mg·L <sup>-1</sup> )
CRINER (2014; STATCOPE) [116]	Multicentre, randomised, parallel group, placebo-controlled (n=885)	Up to 36 months (mean follow-up ~21 months)	Patients 40–80 years old with moderate-to-severe COPD (post-bronchodilator FEV <sub>1</sub> /FVC <70% and FEV <sub>1</sub> <80% pred) and smoking history ≥10 pack-years COPD exacerbation in the previous year <sup>†</sup>	Simvastatin 40 mg once daily (n=433) Placebo (n=452)	Exacerbation rate (number of exacerbations per person-year)	No significant difference in mean exacerbation rate between simvastatin and placebo (1.36 <i>versus</i> 1.39 exacerbations per person-year, respectively)	Median days to first exacerbation was similar for simvastatin (223 days) and placebo (231 days)
INGEBRIGTSEN (2015; Copenhagen General Population Study) [117]	Nested case-control (n=5794)	3 year follow-up	Individuals with COPD and CRP measurement matched for age, sex, smoking, COPD severity and comorbidity	Statins	COPD exacerbations	Statins associated with reduced risk of COPD exacerbations (crude analysis: OR 0.68 [95% CI 0.51–0.91], p=0.01; multivariate analysis: OR 0.67 [95% CI 0.48–0.92], p=0.01)	In a subgroup of patients with the most severe COPD and no CV comorbidity, statins did not reduce risk of COPD exacerbations (OR 1.1, 95% CI 0.5–2.1)
Rossi (2017; GISSI-HF) [118]	Randomised, double-blind, placebo-controlled (n=1060)			Rosuvastatin 10 mg (n=538) Placebo (n=522)	All-cause mortality	There was no significant difference in all-cause mortality between rosuvastatin and placebo (p=0.30)	There were no significant differences in CV death (p=0.88), non-CV death (p=0.09) and all-cause hospitalisation (p=0.82) between rosuvastatin and placebo

Continued

TABLE 2 Continued

Author/study	Design and participants	Duration	Population	Treatment(s)	Primary outcome	Key results	Other findings
<b>Antiplatelet therapy</b>							
EKSTRÖM (2013; national Swevedox register) [119]	Prospective, national multicentre (n=2249)	4 years prior to baseline	Individuals aged $\geq 45$ years with physician-diagnosed COPD treated with LTOT	All dispensed prescriptions in outpatient care in Sweden after July 01, 2005	Comorbidity and in-hospital time	Patients treated with antiplatelet drugs had higher BMI and more CVD, diabetes mellitus and renal failure than patients not on antiplatelets The use of antiplatelet drugs was associated with decreased mortality (HR 0.86 [95% CI 0.75–0.99], $p=0.030$ )	
HARRISON (2014; EXODUS cohort) [120]	Observational, cohort multicentre (n=1343)	1 year	Individuals >40 years old with spirometry-confirmed COPD admitted to hospital between 2009 and 2011 with AECOPD	All COPD and CV medications	1-year all-cause mortality	Antiplatelet therapy was correlated with a reduction in 1-year mortality (OR 0.63 [95% CI 0.47–0.85], $p=0.003$ )	Antiplatelet therapy was not correlated with a reduction in hospital mortality ( $p=0.124$ ), CV hospitalisation ( $p=0.097$ ) or CV death ( $p=0.311$ )
<b>Other CV medications</b>							
HERRIN (2013) [121]	Observational, cohort (n=7104)	Receiving care between January 2001 and December 2006 Follow-up April 2009	Individuals with COPD and hypertension prescribed with two antihypertensive medications	Thiazide diuretic plus $\beta$ -blocker Thiazide diuretic plus ACEI/ARB Thiazide diuretic plus CCB $\beta$ -blocker plus ACEI/ARB	CHF (time to first event requiring hospitalisation)	Choice of antihypertensive medications in combination with a thiazide diuretic had no significant effect on the risk of COPD exacerbations	
ACE: angiotensin-converting enzyme; ACEI: ACE inhibitor; AECOPD: acute exacerbation of COPD; ARB: angiotensin receptor blocker; ARF: acute respiratory failure; BMI: body mass index; CAD: coronary artery disease; CAT: COPD Assessment Test; CCB: calcium channel blocker; CHF: congestive heart failure; CRP: C-reactive protein; CT: computed tomography; CVD: cardiovascular disease; ER: emergency room; FEV <sub>1</sub> : forced expiratory volume in 1 s; FVC: forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HF: heart failure; HR: hazard ratio; hsCRP: high-sensitivity C-reactive protein; IHD: ischaemic heart disease; IRR: incidence risk ratio; LTOT: long-term oxygen therapy; LVEF: left-ventricular ejection fraction; MI: myocardial infarction; NHS: National Health Service; NSAID: non-steroidal anti-inflammatory drug; OR: odds ratio; PAP: pulmonary arterial pressure; $P_{I_{max}}$ : maximal inspiratory pressure; PH: pulmonary hypertension; PVR: pulmonary vascular resistance; $P_{VO_2}$ : mixed venous oxygen tension; RAAS: renin-angiotensin-aldosterone system; SABA: short-acting $\beta_2$ -agonist; TLC: total lung capacity; VA: Veterans Affairs. #: $\beta$ -agonist, inhaled corticosteroid, tiotropium or ipratropium; †: defined by use of supplemental oxygen, systemic glucocorticoids or antibiotic therapy, or presentation to the emergency department or hospitalisation.							

patient cohort data from the Taiwan National Health Insurance Research Database found that new LABA use was associated with an increased risk of a severe CV event within 30 days of therapy (OR 1.50,  $p < 0.001$  compared with non-use of LABA or long-acting muscarinic antagonists (LAMAs)) [123]. However, there was no increase in risk with prevalent (long-term) use. Furthermore, in the SUMMIT (Study to Understand Mortality and Morbidity in COPD) RCT, which was conducted among patients with heightened CV risk, there was no excess of cardiac disorders or arrhythmias among patients treated with the LABA vilanterol compared with a placebo [92]. Observational data regarding new use of short-acting  $\beta_2$ -agonists (SABAs) are also mixed and, in one Canadian database analysis, SABAs did not increase fatal or non-fatal acute myocardial infarction (MI) [71].

There are also data to suggest that  $\beta_2$ -agonists can produce effects that may have a positive impact on CV risk. For example, LABAs provide significant improvements in inspiratory capacity (IC), a marker of lung hyperinflation, *versus* placebo [128–130]. Lung deflation and improvements in QT kinetics and microvascular oxygen delivery have also been observed [81], while improvements in dyspnoea with indacaterol were associated with improvements in indices of right-ventricular compliance [73]. Inhaled LABAs may also have direct beneficial effects on pulmonary haemodynamics (e.g. pulmonary arterial pressure (PAP)) [27] and reduce the rate of COPD exacerbations [70, 131, 132], which are associated with an increased CV risk and mortality [12].

#### **Muscarinic antagonists**

Similar to LABAs, LAMAs have been associated with both positive and negative CV effects. Anti-muscarinic agents may suppress parasympathetic control of heart rate, which could increase the risk of tachyarrhythmias [133]. However, there are various potential mechanisms whereby muscarinic antagonists could lower CV risk, such as by reducing lung hyperinflation [134, 135].

The LAMA tiotropium was shown to reduce lung hyperinflation and improve CV responses to exercise (such as reducing heart rate and blood pressure (BP)) [75]. The reduction in heart rate correlated with an increase in inspiratory reserve volume (IRV) [75], consistent with an observed improvement in CV effects due to mechanical unloading of ventilator muscles. Tiotropium also reduces arterial stiffness [80]. Other potential CV benefits of LAMAs include reduction in exacerbations and an improvement in left-ventricular diastolic function, although not left-ventricular ejection fraction (LVEF) [79].

There are inconsistent results regarding the effects of muscarinic antagonists on CV risk and mortality in COPD. Meta-analyses and cohort analyses reported that muscarinic antagonists, and tiotropium specifically, are not associated with an increase in CV events, risks, or deaths [65, 77]. In contrast, an analysis of Canadian healthcare databases indicated that new ipratropium use was associated with an elevated rate of cardiac arrhythmia in patients with COPD [82, 83] and another meta-analysis reported that ipratropium and tiotropium increased the risk of the composite endpoint of CV mortality, MI and stroke compared with control therapy [76]. However, it has been suggested that the latter meta-analysis had methodological flaws [136], such as the inclusion of many patients from one study and that many CV deaths occurred in patients who were non-compliant with ipratropium. Tiotropium may also have pro-ischaemic and pro-arrhythmic effects [133]. Further data from Taiwan found that new LAMA use (as well as new LABA use) was associated with a 1.52-fold increase in the risk of a severe CV event within 30 days of therapy initiation compared with non-use of a LABA or a LAMA ( $p < 0.001$ ). It was hypothesised that this effect, observed for both LAMAs and LABAs, may be related to sympathetic over-activation or an increase in inflammatory cytokine levels [123]. However, in the same study, there was no risk associated with long-term use [123] and tiotropium has been associated with a trend towards reduced risk for all-cause, CV and respiratory mortality in RCTs [74, 78, 137].

#### **LABA/LAMA combinations**

The CV risk associated with combining long-acting bronchodilators is largely uncertain. A combination of the short-acting bronchodilators salbutamol and ipratropium reduced lung hyperinflation and provided faster QT kinetics as well as larger improvements in microvascular oxygen delivery *versus* placebo [81]. Furthermore, in the CLAIM study [86], the LABA/LAMA combination indacaterol/glycopyrronium significantly improved left-ventricular and right-ventricular end diastolic volumes, QT and peak forced expiratory volume in 1 s (FEV<sub>1</sub>), and induced lung deflation compared with placebo.

Large RCTs have not identified additional CV-associated safety concerns with combining long-acting bronchodilators *versus* monotherapy alone, although studies were not designed to investigate this outcome [64, 138]. Real-world, primary care data indicated that the addition of a second long-acting bronchodilator to existing LABA or tiotropium treatment was not associated with an increased risk of acute MI, stroke or arrhythmia after 1 year compared with monotherapy, but the risk of developing HF was significantly elevated [66]. Furthermore, HF risk increased by 21% when patients with prior HF were removed from the

analysis [66]. The reasons for this elevation are unknown, and further investigation and monitoring are required. However, when comparing LABA/LAMA and ICS/LABA therapy in a retrospective, observational cohort study, CV events were less frequent with LABA/LAMA treatment, with no significant difference observed in the risk of cerebrovascular events [85].

#### ***ICS, ICS/LABA and ICS/LABA/LAMA combinations***

The effects of ICS on systemic inflammation [41, 139, 140] and cardioprotection [87, 88] are unclear. Systemic corticosteroids appear to promote progression of atherogenesis, but may also improve recovery from occlusive vascular events and intravascular injury [141, 142]. Lung deflation with fluticasone furoate/vilanterol improved cardiac function (right-ventricular, left-ventricular and left atrial volumes) *versus* placebo [91]. Treatment with ICS/LABA also reduced arterial stiffness to a similar extent as tiotropium in a study of 257 patients with COPD, suggesting that the long-acting bronchodilator component of the combination drives this effect [80]. However, no reduction in aortic pulse wave velocity (aPWV) was observed compared with placebo [90, 93].

A hypothesis-generating *post hoc* analysis of TORCH (Towards a Revolution in COPD Health) indicated that the ICS/LABA combination salmeterol/fluticasone propionate might have beneficial effects on reducing CV events in certain subgroups of patients, such as those receiving CV medications at baseline or with moderate COPD [89]. The SUMMIT study investigated this hypothesis by comparing fluticasone furoate/vilanterol, respective monotherapies, and placebo in patients with moderate COPD and CVD or multiple CV risk factors [92]. Fluticasone furoate/vilanterol did not significantly reduce the risk of mortality *versus* placebo and there were no significant differences when data were analysed by age, sex, baseline therapy or presence of CVD [92]. In addition, there was no effect on the composite CV endpoint [92]. Why SUMMIT did not reproduce the results of the TORCH *post hoc* analysis is unclear. This could reflect differences in the efficacy of the treatments used, or other methodological considerations related to RCTs [68], as discussed above.

Data on the CV risks or benefits of ICS or ICS/LABA combinations in observational studies are also mixed, with reports that low-dose ICS (50–200 µg·day<sup>-1</sup>) may be associated with a reduction in the risk of acute MI in patients with COPD [87]. Although observational studies have indicated that ICS have benefits on CV mortality, RCTs have not shown any significant effect on CV death [88]. To date, no studies have been designed to investigate the effect of ICS/LABA/LAMA combination therapies on CV events; however, RCTs comparing ICS/LABA/LAMA with LAMA/LAMA or ICS/LABA combinations have provided no evidence of an excess CV risk with triple therapy [143, 144].

#### ***Other COPD treatments***

Phosphodiesterase-4 inhibitors, such as roflumilast, are recommended as an additional therapy on top of triple therapy (a combination of ICS, LABA and LAMA) in inadequately controlled patients in Global Initiative for Chronic Obstructive Lung Disease (GOLD) Group D [1]. Phosphodiesterase inhibitors have anti-inflammatory effects, can reduce the risk of exacerbations [145] and may therefore have beneficial effects on CV events in patients with COPD and increased CV risk. Available data are limited, however, a lower rate of major CV adverse events (AEs) with roflumilast *versus* placebo has been reported [96]. A more recent meta-analysis did not identify any particular CV safety signal with roflumilast, but it did report an increased incidence of some (non-CV) AEs, which led the authors to conclude that further, long-term safety studies were needed [146].

Theophylline, a further possible treatment for COPD, [1] has anti-inflammatory effects [147] and intravenous theophylline reduces pulmonary vascular resistance (PVR) and improves ventricular function [148]. However, high doses of theophylline have been linked to changes in cardiac electrophysiology [149]. Weak associations of theophylline and arrhythmias, AF and supraventricular tachycardias have been suggested by a UK case-control study [95], and a cohort study of 12 301 subjects from Canada indicated that the rate of CV death was greater in users of theophylline (with most deaths occurring in individuals with pre-existing conditions) [94]. While this latter analysis was not specific to patients with COPD, the balance of available data suggests that theophylline should be used with caution in patients with COPD and CVD.

Aside from pharmacological strategies, pulmonary rehabilitation (PR) is recommended for patients with COPD as part of integrated patient management [1]. For those with CVD, it is important to consider both diseases when creating PR programmes [150]. Retrospective analyses and prospective studies provide conflicting insight into the effect of CVD on PR efficacy, with the former suggesting a reduction in the ability to achieve a clinically-important difference in 6-minute walking distance and health status in patients with metabolic diseases *versus* those without [151]. However, when studied prospectively, this effect was not observed [152]. Furthermore, the effect of PR on CVD risk is largely unknown. A systematic review of studies investigating arterial stiffness in response to PR or an exercise-training programme in

COPD patients only found three eligible studies, with conflicting results [153]; however, there may be subpopulations of patients who benefit from PR with regards to CV risk [153].

Finally, as an intervention, smoking cessation has the greatest potential to influence the natural history of COPD [1]. A network meta-analysis of pharmacological and behavioural smoking cessation interventions in CVD patients indicated that varenicline and bupropion were associated with greater abstinence than placebo, with increased efficacy also noted with telephone therapy and individual counselling *versus* usual care [154]. However, a further network meta-analysis found no association between cessation medications and major CV events, although nicotine replacement therapy was associated with an increase in CV events overall (driven predominantly by less serious events) compared with smoking cessation advice alone [155, 156].

In summary, the clinical data suggests that inhaled therapies used in the treatment of COPD are not associated with significant CV risk while smoking cessation remains a core strategy for both COPD and CVD, reducing the overall risk of premature mortality from smoking-related diseases. However, more data are required to establish the long-term safety of COPD pharmacotherapies, particularly among patients at high risk of CV events who are often excluded from COPD clinical trials. Observational studies suggest that new users of LABAs and LAMAs with COPD are at higher risk of CV events compared with non-use of LABAs and LAMAs, which indicates the need to monitor patients with CV comorbidities, particularly when bronchodilator therapies are initiated.

## Effects of CV treatments on COPD

### *β-blockers*

The European Society of Cardiology (ESC) advocates the use of  $\beta$ -blockers in HF patients irrespective of the presence of COPD [52], but advises caution in patients with stable coronary artery disease (CAD) and concurrent COPD [157]. The use of  $\beta$ -blockers in patients with COPD and concurrent CVD has historically been avoided because of concerns about potential adverse pulmonary effects. Bronchial smooth muscle contains adrenergic receptors, primarily of the  $\beta_2$ -subtype, and activation of these receptors by agonists causes bronchodilation [158]. Consequently  $\beta$ -blockers are contraindicated in patients with COPD due to concerns about the potential for acute bronchospasm [159]. Indeed, the non-selective blockade of  $\beta$ -receptors by agents such as propranolol has been shown to inhibit the bronchodilator response to  $\beta_2$ -agonists in patients with COPD [160]. However, concerns over the safety of  $\beta$ -blocker therapy in patients with COPD have resulted in sub-optimal therapy in patients with CVD and comorbid COPD [161, 162].

Data which address these safety concerns are increasing. Selective  $\beta_1$ -blockers (*e.g.* atenolol, bisoprolol and metoprolol) have a 20-fold greater affinity for  $\beta_1$ -receptors *versus*  $\beta_2$ -receptors; thus, this subclass of agents are significantly less likely to induce bronchoconstriction. Clinical trials and large meta-analyses have shown that single-dose and long-term use of selective  $\beta_1$ -blockers does not have a significant effect on FEV<sub>1</sub>,  $\beta$ -agonist response, respiratory symptoms, or overall patient condition compared with patients with COPD not receiving  $\beta_1$ -blockers [163–165]. Indeed, selective  $\beta_1$ -blockers and  $\beta_2$ -agonists may have complementary effects, as the use of  $\beta_1$ -blockers in patients with COPD can sensitise  $\beta_2$ -receptors to  $\beta_2$ -agonists [166]. Clinical hesitance to administer selective  $\beta_1$ -blockers when respiratory conditions are present is reflected in review articles and practice guidelines; however, a Cochrane review found that  $\beta_1$ -blockers in mild-to-moderate reversible airway disease or COPD did not produce adverse respiratory effects [163]. Furthermore, selective  $\beta_1$ -blockers do not increase the risk for moderate or severe exacerbations in patients with asthma [167]. This finding is particularly noteworthy given that airflow obstruction reversibility (following  $\beta_2$ -agonist inhalation) is characteristically greater in asthma than in COPD. Thus, one might expect that patients with asthma would be more vulnerable to the adverse effects of  $\beta$ -blockade than patients with COPD; however, with selective  $\beta_1$ -blockade this appears not to be the case.

Evidence from observational studies suggests that  $\beta$ -blockers are associated with various benefits in patients with COPD with or without CVD, such as reductions in mortality, hospital admissions, emergency room (ER) visits and COPD exacerbations [97–99, 101–103], although these studies may have been affected by biases from immortal and immeasurable time [168–170].

Furthermore, the continued use of  $\beta$ -blockers in COPD patients hospitalised for exacerbation did not result in an increase in in-hospital mortality, 30-day readmission or late mechanical ventilation [100]. However, the use of  $\beta$ -blockers may have little effect on lung function and dynamic hyperinflation [104]. Such data must be interpreted cautiously in the absence of RCT data, particularly given the recent discrepancy between observational and RCT data in CV therapy for COPD discussed below in relation to statins.

### *Renin-angiotensin-aldosterone system inhibitors ACEIs and ARBs*

The renin-angiotensin-aldosterone system (RAAS) has been implicated in various processes in the lungs that may be important in the pathogenesis of COPD, including the induction of pro-inflammatory

modulators, the generation of reactive oxygen species and the development of pulmonary fibrosis [171]. Data on the effects of RAAS inhibitors in patients with COPD are limited, although a couple of small studies have indicated a potential benefit on pulmonary function and haemodynamics [105, 106]. More recently, an analysis of the Multi Ethnic Study of Atherosclerosis (MESA), including individuals in the general population aged 45–84 years who had no clinical evidence of CV disease, found that baseline use of an ACEI or ARB protected against the progression of emphysema, especially when prescribed at high doses [124]. The authors attributed the effects of such RAAS inhibitors to inhibition of transforming growth factor- $\beta$  signalling in the lung, thereby reducing the progression of airspace enlargement.

Unfortunately, the most common side effect of therapy with ACEIs is cough, which develops in 5–20% of patients and may be problematic for patients with COPD. Although uncommon, worsening airflow obstruction has been associated with ACEI treatment, leading to suggestions that these agents be used with caution or as a second-line in patients with COPD [158]. No such safety concerns have been reported with ARBs [158]; indeed, data from an observational cohort study among patients with COPD who used ACEIs or ARBs found that ARBs were associated with fewer COPD complications, including severe exacerbations, pneumonia and mortality, than ACEIs [122]. Although these findings require further confirmation, this may suggest that ARBs are a better choice for patients with COPD requiring treatment with a RAAS inhibitor compared with ACEIs [122].

### Statins

Given the high prevalence of CVD and CV risk factors in COPD [3], many patients with COPD receive statin therapy for the primary or secondary prevention of CVD. The lipid-lowering effects of statins are well documented; however, anti-inflammatory effects have also been observed in the airways and CV tissue [172–176] and therefore these agents could have beneficial effects in COPD. Indeed, statin therapy has been shown to improve Borg dyspnoea scores *versus* placebo in patients with COPD and PH [109] and data from retrospective analyses and prospective observational studies support a role for statins in patients with COPD in terms of reductions in exacerbations, hospitalisations and mortality after an exacerbation [107, 110–112, 114, 117, 177, 178]. However, many of these studies may have been affected by biases from immortal and immeasurable time [179].

In the Rotterdam study, long-term statin use had a beneficial effect on mortality in patients with COPD compared with never use [115]. Observational studies suggest that statins may also be associated with a reduced prevalence of airflow limitation [113] and a reduction in FEV<sub>1</sub> decline [108]. However, an analysis of patients with chronic HF and history of COPD found no favourable effect between statins and all-cause mortality, CV death, non-CV death or all-cause hospitalisation [118]. Indeed, in the STATCOPE study (a randomised placebo-controlled trial of simvastatin in the prevention of COPD exacerbations), statin therapy did not decrease exacerbation rates [116]. However, patients with diabetes and coronary heart disease were not included in this study and therefore a benefit of statin therapy on patients at CV risk cannot be excluded.

### Anticoagulants

Anticoagulants (*e.g.* warfarin and newer agents such as apixaban, dabigatran, edoxaban and rivaroxaban) are often used to prevent future thrombotic events in patients with CVD. It is well known that smoking increases the risk of venous thromboembolism (VTE) [180], but patients with severe COPD are also at increased risk of secondary VTE and mortality is higher in patients who have COPD and VTE *versus* COPD alone [181]. Furthermore, a recent meta-analysis revealed that pulmonary embolism was present in approximately one-sixth of patients who had an acute COPD exacerbation of unknown cause and that these emboli were often in regions indicated for anticoagulant therapy [182]. Thus, use of anticoagulants in at-risk COPD patients may help to reduce future thrombotic-related morbidity and mortality.

### Antiplatelet therapy

Thrombocytosis has been reported in an observational cohort of 1343 patients hospitalised for an acute exacerbation of COPD and antiplatelet therapy correlated with lower 1-year mortality in this study [120]. A national prospective multicentre study also suggests a positive effect of antiplatelet therapy on mortality in patients with COPD [119].

### Other CV medications

Data are limited for the effects of other CV medications in patients with COPD. There are no safety concerns or contraindications regarding the use of calcium channel blockers (CCBs) or aldosterone receptor blockers, such as spironolactone, in patients with COPD [158]. In patients with COPD and hypertension, the use of a thiazide diuretic in combination therapy did not affect the risk of COPD exacerbations [121]. However, respiratory acidosis, a common condition in patients with COPD, may be



further complicated by the effects of diuretics on electrolyte levels and acid–base balance, leading to development of mixed acid–base disorders [183]. For example, treating patients with COPD and HF with high-dose diuretics can result in metabolic acidosis and metabolic alkalosis, in addition to pre-existing respiratory acidosis [183]. Patients with HF with reduced ejection fraction may also be treated with sacubitril/valsartan, a first-in-class angiotensin receptor–neprilysin inhibitor (ARNI) [184]. However, the potential impact of ARNIs on COPD outcomes has not been studied.

Overall, the evidence to support the use of CV therapies in patients with COPD is reassuring. Indeed, there are some data to suggest that RAAS inhibitors and statins have a protective effect on the progression of COPD although outcomes studies specifically designed to assess the effect of therapy on patients with COPD and CV would be welcome. Furthermore, historic concerns about the safety of  $\beta$ -blockers are not borne out by the data, which indicates that this class is beneficial in patients with COPD.

### Recognising and managing comorbid COPD and CVD

Comorbidity in COPD is common and can be fatal. Therefore, in order to treat patients appropriately, physicians should proactively search for prevalent and clinically important comorbidities such as CVD. The three most commonly occurring cardiac comorbidities of COPD are AF, HF and IHD [185]. However, non-specific symptoms such as dyspnoea and fatigue are common to all four diseases and acute exacerbations of each of these conditions can result in exacerbation of respiratory symptoms. Indeed, acute respiratory symptoms invariably have mixed pulmonary and cardiac origin [185]. Diagnosing and managing comorbid COPD and CVD and their exacerbations thus remain challenging [186].

#### Recognition

Given the impact of CVD in COPD, it is important to recognise and treat CVD and CV risk factors (such as smoking, cholesterol and BP) as early as possible, but practical guidance is limited. Numerous guidelines have been published to assist in the differential diagnosis of COPD and CVD in isolation, but few exist in the setting of comorbidity or multimorbidity. However, ROVERSI *et al.* [185] have made important progress in this regard, publishing a set of diagnostic and screening procedures to help differentiate COPD from AF, HF and IHD.

When used in addition to lung function tests, CV risk scores significantly improve the prediction of CV events and mortality in patients with COPD [187]. Over and above guidelines-recommended diagnostic procedures for CVD, further subclinical markers and biomarkers may also assist the assessment and diagnosis of patients in clinical practice. For example, arterial stiffness (as measured by aPWV) has been shown to be predictive of CV events independent of classic CV factors and has been proposed as a surrogate marker of severity [38]. In addition, a prospective cohort study indicated that angiotensin-like protein 4 was independently associated with CV function in patients with COPD [188].

There is also potential for pulmonologists to learn from other specialities that recognise the importance of identifying and managing key comorbidities. For example, diabetes guidelines from the American Diabetes Association recognise the need to look beyond blood glucose, highlighting the importance of effectively managing high BP in patients with diabetes [189].

#### Management

Key international, regional and local guidelines provide limited recommendations on how to manage patients with COPD and CVD [1, 190–192]. The GOLD strategy document states that the presence of comorbidities should not, in general, alter COPD treatment and that comorbidities should be treated as per usual standards, irrespective of the presence of COPD [1].

In approaching the treatment of COPD in HF patients, the ESC advocate the use of  $\beta$ -blockers without contraindication for COPD [52]. Unfortunately, despite no consistent evidence contraindicating concurrent  $\beta$ -blocker and LABA administration, some patients with COPD and CVD are not receiving guideline-based therapies due to historical concerns [63, 193] and patients with HF are less likely to receive  $\beta$ -blockers if they also have COPD [63, 193].

In 2016, the National Institute for Health and Care Excellence published a set of clinical guidelines for the assessment, prioritisation and management of patients with commonly occurring multimorbidities [7]. However, more extensive, integrated recommendations specifically concerning CV risk assessment and management in patients with COPD are necessary to optimise management of comorbid COPD and CVD. Indeed, in order to ascertain the most appropriate treatment in patients with further exacerbations despite treatment with a LABA/LAMA, recent proposals for alternative treatment algorithms advocate the assessment of comorbidities [186]. Adoption of strategies aimed at improving outcomes in these

“cardiopulmonary” patients (*e.g. via* joint management by respiratory and cardiac health professionals in a cardiopulmonary outpatient clinic) is to be encouraged [185].

### Our recommendations

CV diseases are often underdiagnosed and under-treated in patients with COPD [18]. Furthermore, treatment with therapies targeted to treat comorbidities such as HF, IHD, AF and hypertension have the potential to modify the natural history of patients with COPD [115, 124]. We therefore support the active detection and management of comorbidities in COPD and suggest using relevant treatment guidelines for patients without COPD in the absence of more specific information. Our recommendations for clinicians regarding management of patients with both COPD and CVD in clinical practice are as follows: 1) multimorbidity is often overlooked during the diagnosis of an initial (*i.e.* index) chronic disease; however, all patients who have COPD, CVD or another index chronic disease should be evaluated thoroughly to rule out the presence of additional chronic diseases. This is especially important for index diseases such as COPD, in which treatment is purely symptomatic and does not address underlying pathophysiological causes; 2) consider and measure CV risk in every patient with COPD using a validated score (*e.g.* QRISK3 [194]). Where this gives intermediate results, consider an individualised assessment of risk, such as coronary calcium score or pulse wave velocity. Assess diffusion capacity for the differential diagnosis of dyspnoea in COPD; 3) in patients with COPD, manage comorbid CVD and CV risks according to guidelines. Prescribe  $\beta$ -blockers only in accordance with approved indications, use cardioselective  $\beta_1$ -blockers (*e.g.* atenolol, bisoprolol and metoprolol), initiate treatment at the lowest dose and up-titrate slowly. Engage/interact with other medical disciplines to address treating patients with multimorbidity; 4) in patients with COPD, monitor lung hyperinflation routinely *via* IC assessments; 5) reassess risk and control in response to changes in intervention

### Conclusion

COPD and CVD are complex disorders that frequently co-exist and are associated with worse outcomes than either condition alone. Potential mechanisms have been discussed whereby COPD and CVD may interact and treatments for COPD may help to reduce the risk of CVD. These include mechanical offloading of the CV system through reductions in lung hyperinflation, anti-inflammatory effects and the prevention of exacerbations. Current guidelines offer only limited recommendations for the management of CVD in patients with COPD and there is an urgent need for more extensive and specific recommendations to guide physicians in clinical practice.

**Acknowledgements:** The authors were assisted in the preparation of the manuscript by Graham Allcock and Elizabeth Andrew (professional medical writers, CircleScience (an Ashfield company, part of UDG Healthcare plc), Tytherington, UK) and Laura Elson (a professional medical writer contracted to CircleScience). Medical writing support was funded by Novartis Pharma AG (Basel, Switzerland).

**Conflict of interest:** K.F. Rabe reports personal fees (consultant and speakers fees) from AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi, Teva, Intermune, Chiesi Pharmaceuticals and Berlin Chemie, as well as grants from the Ministry of Education and Science, Germany, outside the submitted work. J. Hurst reports grants, personal fees and non-financial support from pharmaceutical companies that make medicines to treat COPD, outside the submitted work. S. Suissa reports grants and personal fees (board membership and research grant) from Novartis and Boehringer Ingelheim, and personal fees (lectures) from AstraZeneca, outside the submitted work.

**Support statement:** This study was funded by Novartis. Funding information for this article has been deposited with the Crossref Funder Registry.

### References

- 1 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). [https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov\\_WMS.pdf](https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf) Date last accessed: November 28, 2017.
- 2 Divo M, Cote C, de Torres JP, *et al.* Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012; 186: 155–161.
- 3 Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2014; 9: 871–888.
- 4 van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what’s in a name? A review of literature. *Eur J Gen Pract* 1996; 2: 65–70.
- 5 Bhatt SP, Dransfield MT. AECOPD: acute exacerbations of chronic obstructive cardiopulmonary disease? *Am J Respir Crit Care Med* 2013; 188: 1046–1048.
- 6 Ording AG, Sorensen HT. Concepts of comorbidities, multiple morbidities, complications, and their clinical epidemiologic analogs. *Clin Epidemiol* 2013; 5: 199–203.
- 7 National Guideline Centre. Multimorbidity: clinical assessment and management: assessment, prioritisation and management of care for people with commonly occurring multimorbidity (NICE guideline NG56). London, National Institute for Health and Care Excellence, 2016. [www.nice.org.uk/guidance/ng56/evidence/full-guideline-pdf-2615543103](http://www.nice.org.uk/guidance/ng56/evidence/full-guideline-pdf-2615543103) Date last updated: December 06, 2016.

- 8 Miller J, Edwards LD, Agusti A, *et al.* Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. *Respir Med* 2013; 107: 1376–1384.
- 9 Mannino DM, Thorn D, Swensen A, *et al.* Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur Respir J* 2008; 32: 962–969.
- 10 Westerik JA, Metting EI, van Boven JF, *et al.* Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. *Respir Res* 2017; 18: 31.
- 11 Lahousse L, Tiemeier H, Ikram MA, *et al.* Chronic obstructive pulmonary disease and cerebrovascular disease: a comprehensive review. *Respir Med* 2015; 109: 1371–1380.
- 12 Donaldson GC, Hurst JR, Smith CJ, *et al.* Increased risk of myocardial infarction and stroke following exacerbation of COPD. *Chest* 2010; 137: 1091–1097.
- 13 Speizer FE, Fay ME, Dockery DW, *et al.* Chronic obstructive pulmonary disease mortality in six U.S. cities. *Am Rev Respir Dis* 1989; 140: S49–S55.
- 14 Corrao S, Brunori G, Lupo U, *et al.* Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities. *Eur Respir Rev* 2017; 26: 160123.
- 15 Lahousse L, Verhamme KM, Stricker BH, *et al.* Cardiac effects of current treatments of chronic obstructive pulmonary disease. *Lancet Respir Med* 2016; 4: 149–164.
- 16 Brook RD, Anderson JA, Calverley PM, *et al.* Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. *Heart* 2017; 103: 1536–1542.
- 17 Cazzola M, Calzetta L, Rinaldi B, *et al.* Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. *Drugs* 2017; 77: 721–732.
- 18 Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? *Ther Adv Respir Dis* 2018; 12: <https://doi.org/10.1177/1753465817750524>
- 19 Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. *Chest* 2013; 143: 798–807.
- 20 Ghoorah K, De Soyza A, Kunadian V. Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review. *Cardiol Rev* 2013; 21: 196–202.
- 21 Rossi A, Aisanov Z, Avdeev S, *et al.* Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. *Respir Med* 2015; 109: 785–802.
- 22 O'Donnell DE, Webb KA, Neder JA. Lung hyperinflation in COPD: applying physiology to clinical practice. *COPD Research and Practice* 2015; 1: 4.
- 23 Parshall MB, Schwartzstein RM, Adams L, *et al.* An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. *Am J Respir Crit Care Med* 2012; 185: 435–452.
- 24 Rennard SI. Clinical approach to patients with chronic obstructive pulmonary disease and cardiovascular disease. *Proc Am Thorac Soc* 2005; 2: 94–100.
- 25 Watz H, Waschki B, Meyer T, *et al.* Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. *Chest* 2010; 138: 32–38.
- 26 Barr RG, Bluemke DA, Ahmed FS, *et al.* Percent emphysema, airflow obstruction, and impaired left ventricular filling. *N Engl J Med* 2010; 362: 217–227.
- 27 Cazzola M, Mantero A, Santus P, *et al.* Doppler echocardiographic assessment of the effects of inhaled long-acting  $\beta_2$ -agonists on pulmonary artery pressure in COPD patients. *Pulm Pharmacol Ther* 2007; 20: 258–264.
- 28 Smith BM, Kawut SM, Bluemke DA, *et al.* Pulmonary hyperinflation and left ventricular mass: the Multi-Ethnic Study of Atherosclerosis COPD Study. *Circulation* 2013; 127: 1503–1506.
- 29 Smith BM, Prince MR, Hoffman EA, *et al.* Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study. *Chest* 2013; 144: 1143–1151.
- 30 Ferguson GT. Why does the lung hyperinflate? *Proc Am Thorac Soc* 2006; 3: 176–179.
- 31 Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. *Int J Chron Obstruct Pulmon Dis* 2011; 6: 199–208.
- 32 Zangiabadi A, De Pasquale CG, Sajkov D. Pulmonary hypertension and right heart dysfunction in chronic lung disease. *Biomed Res Int* 2014; 2014: 739674.
- 33 Boussuges A, Pinet C, Molenat F, *et al.* Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study. *Am J Respir Crit Care Med* 2000; 162: 670–675.
- 34 Louie EK, Rich S, Levitsky S, *et al.* Doppler echocardiographic demonstration of the differential effects of right ventricular pressure and volume overload on left ventricular geometry and filling. *J Am Coll Cardiol* 1992; 19: 84–90.
- 35 Sievi NA, Clarenbach CF, Camen G, *et al.* High prevalence of altered cardiac repolarization in patients with COPD. *BMC Pulm Med* 2014; 14: 55.
- 36 Drakopoulou M, Toutouzias K, Michelongona A, *et al.* Vulnerable plaque and inflammation: potential clinical strategies. *Curr Pharm Des* 2011; 17: 4190–4209.
- 37 Linden F, Domschke G, Erbel C, *et al.* Inflammatory therapeutic targets in coronary atherosclerosis—from molecular biology to clinical application. *Front Physiol* 2014; 5: 455.
- 38 Vivodtzev I, Tamisier R, Baguet JP, *et al.* Arterial stiffness in COPD. *Chest* 2014; 145: 861–875.
- 39 Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2005; 2: 26–33.
- 40 Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. *Circulation* 2003; 107: 1514–1519.
- 41 Sin DD, Man SF, Marciniuk DD, *et al.* The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2008; 177: 1207–1214.
- 42 Williams MC, Murchison JT, Edwards LD, *et al.* Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. *Thorax* 2014; 69: 718–723.
- 43 Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. *Eur Respir J* 2009; 33: 1165–1185.

- 44 Kunisaki KM, Dransfield MT, Anderson JA, *et al.* Exacerbations of chronic obstructive pulmonary disease and cardiac events: a cohort analysis. *Am J Respir Crit Care Med* 2018; 198: 51–557.
- 45 Liu Y, Liu X, Lin G, *et al.* Decreased CD34+ cell number is correlated with cardiac dysfunction in patients with acute exacerbation of COPD. *Heart Lung Circ* 2014; 23: 875–882.
- 46 Kersul AL, Iglesias A, Rios A, *et al.* Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. *Arch Bronconeumol* 2011; 47: 176–183.
- 47 Maclay JD, McAllister DA, Johnston S, *et al.* Increased platelet activation in patients with stable and acute exacerbation of COPD. *Thorax* 2011; 66: 769–774.
- 48 Mills NL, Miller JJ, Anand A, *et al.* Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. *Thorax* 2008; 63: 306–311.
- 49 Patel AR, Kowlessar BS, Donaldson GC, *et al.* Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013; 188: 1091–1099.
- 50 Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. *Chest* 2009; 135: 173–180.
- 51 Lee JH, Cho MH, Hersh CP, *et al.* Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease. *Respir Res* 2014; 15: 113.
- 52 Ponikowski P, Voors AA, Anker SD, *et al.* 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2016; 37: 2129–2200.
- 53 Poole DC, Richardson RS, Haykowsky MJ, *et al.* Exercise limitations in heart failure with reduced and preserved ejection fraction. *J Appl Physiol* 2018; 124: 208–224.
- 54 Agostoni P, Cattadori G, Guazzi M, *et al.* Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. *Am Heart J* 2000; 140: e24.
- 55 Agostoni P, Bussotti M, Cattadori G, *et al.* Gas diffusion and alveolar-capillary unit in chronic heart failure. *Eur Heart J* 2006; 27: 2538–2543.
- 56 Wasserman K, Zhang YY, Gitt A, *et al.* Lung function and exercise gas exchange in chronic heart failure. *Circulation* 1997; 96: 2221–2227.
- 57 Patel AR, Donaldson GC, Mackay AJ, *et al.* The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. *Chest* 2012; 141: 851–857.
- 58 Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. *Lancet Respir Med* 2013; 1: 73–83.
- 59 Vestbo J. Systemic inflammation and progression of COPD. *Thorax* 2007; 62: 469–470.
- 60 Yndestad A, Damas JK, Oie E, *et al.* Systemic inflammation in heart failure—the whys and wherefores. *Heart Fail Rev* 2006; 11: 83–92.
- 61 Kanazawa H, Hirata K, Yoshikawa J. Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients. *Chest* 2003; 123: 596–599.
- 62 Almagro P, Salvado M, Garcia-Vidal C, *et al.* Recent improvement in long-term survival after a COPD hospitalisation. *Thorax* 2010; 65: 298–302.
- 63 Fisher KA, Stefan MS, Darling C, *et al.* Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study. *Chest* 2015; 147: 637–645.
- 64 Kardos P, Worsley S, Singh D, *et al.* Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 2885–2895.
- 65 Suissa S, Dell’Aniello S, Ernst P. Long-acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary events: a population-based comparative safety study. *Chest* 2017; 151: 60–67.
- 66 Suissa S, Dell’Aniello S, Ernst P. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. *Eur Respir J* 2017; 49: 1602245.
- 67 Suissa S, Ernst P, Vandemheen KL, *et al.* Methodological issues in therapeutic trials of COPD. *Eur Respir J* 2008; 31: 927–933.
- 68 Suissa S. Will SUMMIT reach the peak in COPD? *Thorax* 2014; 69: 405–407.
- 69 Suissa S. Run-in bias in randomised trials: the case of COPD medications. *Eur Respir J* 2017; 49: 1700361.
- 70 Calverley PM, Anderson JA, Celli B, *et al.* Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 2007; 356: 775–789.
- 71 Suissa S, Assimes T, Ernst P. Inhaled short acting  $\beta$ -agonist use in COPD and the risk of acute myocardial infarction. *Thorax* 2003; 58: 43–46.
- 72 Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of  $\beta$ -agonists in patients with asthma and COPD: a meta-analysis. *Chest* 2004; 125: 2309–2321.
- 73 Santus P, Radovanovic D, Di Marco S, *et al.* Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 1917–1923.
- 74 Kesten S, Jara M, Wentworth C, *et al.* Pooled clinical trial analysis of tiotropium safety. *Chest* 2006; 130: 1695–1703.
- 75 Travers J, Laveneziana P, Webb KA, *et al.* Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. *Respir Med* 2007; 101: 2017–2024.
- 76 Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *JAMA* 2008; 300: 1439–1450.
- 77 Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, *et al.* Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. *Respir Med* 2009; 103: 1421–1429.
- 78 Celli B, Decramer M, Kesten S, *et al.* Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2009; 180: 948–955.
- 79 Nojiri T, Yamamoto K, Maeda H, *et al.* Effects of inhaled tiotropium on left ventricular diastolic function in chronic obstructive pulmonary disease patients after pulmonary resection. *Ann Thorac Cardiovasc Surg* 2012; 18: 206–211.

- 80 Pepin JL, Cockcroft JR, Midwinter D, *et al.* Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. *Chest* 2014; 146: 1521–1530.
- 81 Berton DC, Barbosa PB, Takara LS, *et al.* Bronchodilators accelerate the dynamics of muscle O<sub>2</sub> delivery and utilisation during exercise in COPD. *Thorax* 2010; 65: 588–593.
- 82 Wilchesky M, Ernst P, Brophy JM, *et al.* Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. *Chest* 2012; 142: 298–304.
- 83 Wilchesky M, Ernst P, Brophy JM, *et al.* Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. *Chest* 2012; 142: 305–311.
- 84 Gershon A, Croxford R, Calzavara A, *et al.* Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. *JAMA Intern Med* 2013; 173: 1175–1185.
- 85 Samp JC, Joo MJ, Schumock GT, *et al.* Risk of cardiovascular and cerebrovascular events in COPD patients treated with long-acting  $\beta_2$ -agonist combined with a long-acting muscarinic or inhaled corticosteroid. *Ann Pharmacother* 2017; 51: 945–953.
- 86 Hohlfield JM, Vogel-Claussen J, Biller H, *et al.* Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. *Lancet Respir Med* 2018; 6: 368–378.
- 87 Huiart L, Ernst P, Ranouil X, *et al.* Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. *Eur Respir J* 2005; 25: 634–639.
- 88 Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. *Eur Respir J* 2010; 35: 1003–1021.
- 89 Calverley PM, Anderson JA, Celli B, *et al.* Cardiovascular events in patients with COPD: TORCH study results. *Thorax* 2010; 65: 719–725.
- 90 Dransfield MT, Cockcroft JR, Townsend RR, *et al.* Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. *Respir Med* 2011; 105: 1322–1330.
- 91 Stone IS, Barnes NC, James WY, *et al.* Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease: a randomized controlled trial. *Am J Respir Crit Care Med* 2016; 193: 717–726.
- 92 Vestbo J, Anderson JA, Brook RD, *et al.* Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. *Lancet* 2016; 387: 1817–1826.
- 93 Bhatt SP, Dransfield MT, Cockcroft JR, *et al.* A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 351–365.
- 94 Suissa S, Hemmelgarn B, Blais L, *et al.* Bronchodilators and acute cardiac death. *Am J Respir Crit Care Med* 1996; 154: 1598–1602.
- 95 Huerta C, Lanes SF, Garcia Rodriguez LA. Respiratory medications and the risk of cardiac arrhythmias. *Epidemiology* 2005; 16: 360–366.
- 96 White WB, Cooke GE, Kowey PR, *et al.* Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. *Chest* 2013; 144: 758–765.
- 97 Dransfield MT, Rowe SM, Johnson JE, *et al.* Use of  $\beta$  blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. *Thorax* 2008; 63: 301–305.
- 98 Rutten FH, Zuithoff NP, Hak E, *et al.*  $\beta$ -blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. *Arch Intern Med* 2010; 170: 880–887.
- 99 Short PM, Lipworth SI, Elder DH, *et al.* Effect of  $\beta$  blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. *BMJ* 2011; 342: d2549.
- 100 Stefan MS, Rothberg MB, Priya A, *et al.* Association between  $\beta$ -blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. *Thorax* 2012; 67: 977–984.
- 101 Du Q, Sun Y, Ding N, *et al.* Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. *PLoS One* 2014; 9: e113048.
- 102 Puente-Maestu L, Calle M, Ortega-Gonzalez A, *et al.* Multicentric study on the beta-blocker use and relation with exacerbations in COPD. *Respir Med* 2014; 108: 737–744.
- 103 Bhatt SP, Wells JM, Kinney GL, *et al.*  $\beta$ -Blockers are associated with a reduction in COPD exacerbations. *Thorax* 2016; 71: 8–14.
- 104 Key A, Parry M, West MA, *et al.* Effect of  $\beta$ -blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD. *BMJ Open Respir Res* 2017; 4: e000164.
- 105 Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. *Thorax* 2003; 58: 629–631.
- 106 Andreas S, Herrmann-Lingen C, Raupach T, *et al.* Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. *Eur Respir J* 2006; 27: 972–979.
- 107 Mancini GB, Etmnan M, Zhang B, *et al.* Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. *J Am Coll Cardiol* 2006; 47: 2554–2560.
- 108 Alexeeff SE, Litonjua AA, Sparrow D, *et al.* Statin use reduces decline in lung function: VA Normative Aging study. *Am J Respir Crit Care Med* 2007; 176: 742–747.
- 109 Lee TM, Chen CC, Shen HN, *et al.* Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. *Clin Sci (Lond)* 2009; 116: 497–505.
- 110 Mortensen EM, Copeland LA, Pugh MJ, *et al.* Impact of statins and ACE inhibitors on mortality after COPD exacerbations. *Respir Res* 2009; 10: 45.
- 111 Bartziokas K, Papaioannou AI, Minas M, *et al.* Statins and outcome after hospitalization for COPD exacerbation: a prospective study. *Pulm Pharmacol Ther* 2011; 24: 625–631.
- 112 Huang CC, Chan WL, Chen YC, *et al.* Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. *Clin Ther* 2011; 33: 1365–1370.

- 113 Bando M, Miyazawa T, Shinohara H, *et al.* An epidemiological study of the effects of statin use on airflow limitation in patients with chronic obstructive pulmonary disease. *Respirology* 2012; 17: 493–498.
- 114 Wang MT, Lo YW, Tsai CL, *et al.* Statin use and risk of COPD exacerbation requiring hospitalization. *Am J Med* 2013; 126: 598–606.
- 115 Lahousse L, Loth DW, Joos GF, *et al.* Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. *Pulm Pharmacol Ther* 2013; 26: 212–217.
- 116 Criner GJ, Connett JE, Aaron SD, *et al.* Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. *N Engl J Med* 2014; 370: 2201–2210.
- 117 Ingebrigtsen TS, Marott JL, Nordestgaard BG, *et al.* Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. *Thorax* 2015; 70: 33–40.
- 118 Rossi A, Inciardi RM, Rossi A, *et al.* Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: a sub-analysis of GISSI-HF trial. *Pulm Pharmacol Ther* 2017; 44: 16–23.
- 119 Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013; 187: 715–720.
- 120 Harrison MT, Short P, Williamson PA, *et al.* Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? *Thorax* 2014; 69: 609–615.
- 121 Herrin MA, Feemster LC, Crothers K, *et al.* Combination antihypertensive therapy among patients with COPD. *Chest* 2013; 143: 1312–1320.
- 122 Lai CC, Wang YH, Wang CY, *et al.* Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 867–874.
- 123 Wang MT, Liou JT, Lin CW, *et al.* Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-Control Study. *JAMA Intern Med* 2018; 178: 229–238.
- 124 Parikh MA, Aaron CP, Hoffman EA, *et al.* Angiotensin-converting inhibitors and angiotensin II receptor blockers and longitudinal change in percent emphysema on computed tomography. The Multi-Ethnic Study of Atherosclerosis lung study. *Ann Am Thorac Soc* 2017; 14: 649–658.
- 125 Au DH, Lemaitre RN, Curtis JR, *et al.* The risk of myocardial infarction associated with inhaled  $\beta$ -adrenoceptor agonists. *Am J Respir Crit Care Med* 2000; 161: 827–830.
- 126 Tashkin DP, Celli B, Senn S, *et al.* A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med* 2008; 359: 1543–1554.
- 127 Iftikhar IH, Imtiaz M, Brett AS, *et al.* Cardiovascular safety of long acting beta agonist-inhaled corticosteroid combination products in adult patients with asthma: a systematic review. *Lung* 2014; 192: 47–54.
- 128 Laforce C, Aumann J, de Teresa Parreño L, *et al.* Sustained 24-hour efficacy of once daily indacaterol (300  $\mu$ g) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. *Pulm Pharmacol Ther* 2011; 24: 162–168.
- 129 Mahler DA, D'Urzo A, Bateman ED, *et al.* Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. *Thorax* 2012; 67: 781–788.
- 130 Beier J, Beeh KM, Brookman L, *et al.* Bronchodilator effects of indacaterol and formoterol in patients with COPD. *Pulm Pharmacol Ther* 2009; 22: 492–496.
- 131 Dahl R, Chung KF, Buhl R, *et al.* Efficacy of a new once-daily long-acting inhaled  $\beta_2$ -agonist indacaterol versus twice-daily formoterol in COPD. *Thorax* 2010; 65: 473–479.
- 132 Donohue JF, Fogarty C, Lötvall J, *et al.* Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. *Am J Respir Crit Care Med* 2010; 182: 155–162.
- 133 Singh S, Loke YK, Enright P, *et al.* Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. *Thorax* 2013; 68: 114–116.
- 134 O'Donnell DE, Fluge T, Gerken F, *et al.* Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. *Eur Respir J* 2004; 23: 832–840.
- 135 Sanguinetti CM. The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients. *Multidiscip Respir Med* 2014; 9: 19.
- 136 Hilleman DE, Malesker MA, Morrow LE, *et al.* A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2009; 4: 253–263.
- 137 Burgel PR, Paillasseur JL, Dusser D, *et al.* Tiotropium might improve survival in subjects with COPD at high risk of mortality. *Respir Res* 2014; 15: 64.
- 138 Calverley PMA, Anzueto AR, Carter K, *et al.* Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. *Lancet Respir Med* 2018; 6: 337–344.
- 139 Williamson PA, Menzies D, Clearie KL, *et al.* Dose-response for inhaled fluticasone on airway and systemic inflammation in COPD. *Eur Respir J* 2011; 37: 206–209.
- 140 Sin DD, Lacy P, York E, *et al.* Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004; 170: 760–765.
- 141 Walker BR. Glucocorticoids and cardiovascular disease. *Eur J Endocrinol* 2007; 157: 545–559.
- 142 Enc Y, Karaca P, Ayoglu U, *et al.* The acute cardioprotective effect of glucocorticoid in myocardial ischemia-reperfusion injury occurring during cardiopulmonary bypass. *Heart Vessels* 2006; 21: 152–156.
- 143 Papi A, Vestbo J, Fabbri L, *et al.* Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet* 2018; 391: 1076–1084.
- 144 Lipson DA, Barnacle H, Birk R, *et al.* FULFIL trial: once-daily triple therapy in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2017; 196: 438–446.
- 145 Tashkin DP. Roflumilast: the new orally active, selective phosphodiesterase-4 inhibitor, for the treatment of COPD. *Expert Opin Pharmacother* 2014; 15: 85–96.

- 146 Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. *Pulm Pharmacol Ther* 2014; 27: 83–89.
- 147 Barnes PJ. Theophylline. *Am J Respir Crit Care Med* 2013; 188: 901–906.
- 148 Matthay RA, Mahler DA. Theophylline improves global cardiac function and reduces dyspnea in chronic obstructive lung disease. *J Allergy Clin Immunol* 1986; 78: 793–799.
- 149 Eiriksson CE J, Writer SL, Vestal RE. Theophylline-induced alterations in cardiac electrophysiology in patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1987; 135: 322–326.
- 150 Triest FJ, Singh SJ, Vanfleteren LE. Cardiovascular risk, chronic obstructive pulmonary disease and pulmonary rehabilitation: can we learn from cardiac rehabilitation? *Chron Respir Dis* 2016; 13: 286–294.
- 151 Crisafulli E, Costi S, Luppi F, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. *Thorax* 2008; 63: 487–492.
- 152 Crisafulli E, Gorgone P, Vagaggini B, et al. Efficacy of standard rehabilitation in COPD outpatients with comorbidities. *Eur Respir J* 2010; 36: 1042–1048.
- 153 Aldabayan YS, Alrajeh AM, Lemson A, et al. Pulmonary rehabilitation and cardiovascular risk in COPD: a systematic review. *COPD Research and Practice* 2017; 3: 7.
- 154 Suissa K, Lariviere J, Eisenberg MJ, et al. Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. *Circ Cardiovasc Qual Outcomes* 2017; 10: e002458.
- 155 Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. *Circulation* 2014; 129: 28–41.
- 156 Dollerup J, Vestbo J, Murray-Thomas T, et al. Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. *Clin Epidemiol* 2017; 9: 231–243.
- 157 Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. *Eur Heart J* 2013; 34: 2949–3003.
- 158 Chandy D, Aronow WS, Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. *Integr Blood Press Control* 2013; 6: 101–109.
- 159 Matera MG, Calzetta L, Cazzola M.  $\beta$ -Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. *Drugs* 2013; 73: 1653–1663.
- 160 Chang CL, Mills GD, McLachlan JD, et al. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. *Intern Med J* 2010; 40: 193–200.
- 161 Hawkins NM, Wang D, Petrie MC, et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. *Eur J Heart Fail* 2010; 12: 557–565.
- 162 Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. *J Am Coll Cardiol* 2010; 55: 1780–1787.
- 163 Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2005; 4: CD003566.
- 164 Albouaini K, Andron M, Alahmar A, et al. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. *Int J Chron Obstruct Pulmon Dis* 2007; 2: 535–540.
- 165 Kargin F, Takir HB, Salturk C, et al. The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit. *Multidiscip Respir Med* 2014; 9: 8.
- 166 Salpeter SR. Cardioselective beta blocker use in patients with asthma and chronic obstructive pulmonary disease: an evidence-based approach to standards of care. *Cardiovasc Rev Rep* 2003; 24: 11.
- 167 Morales DR, Lipworth BJ, Donnan PT, et al. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. *BMC Med* 2017; 15: 18.
- 168 Lalmohamed A, Stojanovic D, Durand M, et al. Benefits of beta blockers in COPD patients and immortal/immeasurable time bias *BMJ* 2011; 342: d2549.
- 169 Suissa S, Ernst P. Biases in the observational study of  $\beta$  blockers in COPD. *Thorax* 2008; 63: 1026–1027.
- 170 Suissa S, Ernst P.  $\beta$ -blockers for COPD inpatients. *Thorax* 2012; 67: 936–937.
- 171 Shrikrishna D, Astin R, Kemp PR, et al. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. *Clin Sci (Lond)* 2012; 123: 487–498.
- 172 Davis BB, Zeki AA, Bratt JM, et al. Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy. *Eur Respir J* 2013; 42: 350–361.
- 173 Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1 $\beta$ , interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. *Life Sci* 2000; 67: 863–876.
- 174 Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. *Circulation* 2003; 108: 1560–1566.
- 175 Neukamm A, Hoiseith AD, Einvik G, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. *J Intern Med* 2015; 278: 59–67.
- 176 Wang W, Le W, Ahuja R, et al. Inhibition of inflammatory mediators: role of statins in airway inflammation. *Otolaryngol Head Neck Surg* 2011; 144: 982–987.
- 177 Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. *Int J Clin Pract* 2008; 62: 1373–1378.
- 178 Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. *Eur Respir J* 2007; 29: 279–283.
- 179 Suissa S. Co-morbidity in COPD: the effects of cardiovascular drug therapies. *Respiration* 2010; 80: 3–7.
- 180 Cheng YJ, Liu ZH, Yao FJ, et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. *PLoS Med* 2013; 10: e1001515.
- 181 Borvik T, Braekkan SK, Enga K, et al. COPD and risk of venous thromboembolism and mortality in a general population. *Eur Respir J* 2016; 47: 473–481.

- 182 Aleva FE, Voets L, Simons SO, *et al.* Prevalence and localization of pulmonary embolism in unexplained acute  
exacerbations of COPD: a systematic review and meta-analysis. *Chest* 2017; 151: 544–554.
- 183 Bruno CM, Valenti M. Acid-base disorders in patients with chronic obstructive pulmonary disease:  
a pathophysiological review. *J Biomed Biotechnol* 2012; 2012: 915150.
- 184 McMurray JJ, Packer M, Desai AS, *et al.* Angiotensin-neprilysin inhibition versus enalapril in heart failure.  
*N Engl J Med* 2014; 371: 993–1004.
- 185 Roversi S, Fabbri LM, Sin DD, *et al.* Chronic obstructive pulmonary disease and cardiac diseases. An urgent need  
for integrated care. *Am J Respir Crit Care Med* 2016; 194: 1319–1336.
- 186 Miravittles M, D'Urzo A, Singh D, *et al.* Pharmacological strategies to reduce exacerbation risk in COPD:  
a narrative review. *Respir Res* 2016; 17: 112.
- 187 Lee HM, Lee J, Lee K, *et al.* Relation between COPD severity and global cardiovascular risk in US adults. *Chest*  
2012; 142: 1118–1125.
- 188 Waschki B, Kirsten AM, Holz O, *et al.* Angiotensin-like protein 4 and cardiovascular function in COPD. *BMJ  
Open Respir Res* 2016; 3: e000161.
- 189 Standards of medical care in diabetes – 2014. *Diabetes Care* 2014; 37: Suppl. 1, S14–S80.
- 190 Miravittles M, Soler-Cataluna JJ, Calle M, *et al.* Spanish guidelines for management of chronic obstructive  
pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. *Arch Bronconeumol* 2017; 53:  
324–335.
- 191 Montes de Oca M, Lopez Varela MV, Acuna A, *et al.* ALAT-2014 chronic obstructive pulmonary disease  
(COPD) clinical practice guidelines: questions and answers. *Arch Bronconeumol* 2015; 51: 403–416.
- 192 National Clinical Guideline Centre. Management of chronic obstructive pulmonary disease in adults in primary  
and secondary care (clinical guideline CG101). London, National Clinical Guideline Centre, 2010. [www.nice.org.  
uk/guidance/cg101/evidence/full-guideline-pdf-134519581](http://www.nice.org.uk/guidance/cg101/evidence/full-guideline-pdf-134519581) Date last updated: June 22, 2010.
- 193 Tavazzi L, Swedberg K, Komajda M, *et al.* Clinical profiles and outcomes in patients with chronic heart failure  
and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. *Int J Cardiol* 2013;  
170: 182–188.
- 194 Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to  
estimate future risk of cardiovascular disease: prospective cohort study. *BMJ* 2017; 357: j2099.